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The pluripotent state of embryonic stem cells (ESCs) is shaped by complex 
interactions between multiple genes, transcripts and proteins that form the ESC 
regulatory network. During differentiation, ESCs exit from pluripotency by shutting 
down this network. As the potential of human ESCs (hESCs) lies in their ability to 
differentiate into any specific somatic lineage, it is imperative to understand the 
genetic regulations governing the exit from pluripotency. In this thesis, we report the 
first high-throughput RNA interference screen for factors crucial for the exit from 
pluripotency of hESCs in a comprehensive set of differentiation conditions. This 
systematic study enabled the identification of both centrally important and context-
dependent processes for the exit from pluripotency. Strikingly, we found that the cell 
cycle is a critical process deterministically regulating the exit from pluripotency. Cell 
cycle factors that primarily operate during the S and G2 phases, such as the 
ATM/ATR pathway and Cyclin B1, actively promote the pluripotent state and inhibit 
differentiation. Altogether, this study uncovers a multitude of novel regulators of the 
exit from pluripotency, and establishes a new paradigm where the pluripotency 
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Proper growth and development of an organism is contingent on the precise 
balance of cells’ decision between proliferation and specialization. The ability of cells 
to proliferate is regulated by the complex regulatory program known as the cell cycle. 
Specialization on the other hand is dictated by signalling cues that influence cell fate, 
and is often accompanied by a cessation of proliferation. Therefore, tight cross-
regulation between the cell cycle and fate specification pathways underlies proper 
development (Budirahardja and Gonczy, 2009). This is exceptionally important for 
early embryonic development, which entails extensive growth and the earliest fate 
decisions. For example, pluripotent stem cells across animal species undergo rapid 
and successive cell divisions in order to give rise to the appropriate number of more 
specialized progeny (Edgar and Lehner, 1996; Lawson et al., 1991; Murray and 
Kirschner, 1989; Yarden and Geiger, 1996). This process of self-renewal necessitates 
a unique transcriptional network governing pluripotency coupled with a distinct cell 
cycle profile (Singh and Dalton, 2009). Therefore, thorough understanding of both 
pluripotency and cell cycle regulatory networks is necessary to grasp a complete 
comprehension of early development.   
 
I. Embryonic stem cells 
Past studies of early development rely heavily on animal models in which it is 
ethical and convenient to extrinsically manipulate developmental processes at any 
embryonic stage. However, differences in the developmental progression between 
humans and even the closest animal models are evident. Therefore, an in vitro 
alternative to study human development would prove to be practical; a niche that was 
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fulfilled upon the derivation of embryonic stem cells (ESCs) from the inner cell mass 
of human blastocyst-stage embryos (Cowan et al., 2004; Thomson et al., 1998).  
 
A. Potential applications of ESCs 
ESCs have the ability to self-renew indefinitely in an undifferentiated state in 
vitro. They harbour the developmental potency to give rise to all cell types in the 
embryo proper, and are thus called pluripotent. These properties of ESCs make them 
ideal sources for generating substantial amounts of specific tissues for tissue 
replacement therapies (Figure 1), offering great promise in regenerative medicine. 
ESC-derived tissues can also be used for preliminary assessment of drug efficacy and 
toxicity, extending the clinical applications of ESCs (Figure 1).  
Of course, ESCs also serve as an attractive cellular model to understand 
normal early developmental processes and development-related diseases (Figure 1). 
ESCs act as a convenient in vitro platform for dissecting the multitude of factors 
including transcriptional networks, signalling pathways, non-coding RNAs, epigenetic 
modifications and other processes that facilitate pluripotency maintenance and 
differentiation. As such, numerous studies have put effort in scrutinising the intricate 
machinery behind the ESC state. 





B. Challenges for the applications of human ESCs 
However, use of human ESCs (hESCs) for clinical and scientific use is met 
with several obstacles. For example, hESC derivation methods require an exposure to 
animal-derived products (Vazin and Freed, 2010), which could potentially transfer 
pathogens that would endanger patients receiving ESC-derived transplantations. 
There is also the significant barrier of immune-mediated rejection of hESC-derived 
tissues due to genetic differences between the ESC donor and recipient (Drukker, 
2008). Generation of hESC lines also obligates the destruction of the embryonic 
source (Vazin and Freed, 2010), which imposes ethical and socio-political issues. To 
address these, several alternative sources of human pluripotent cells have been 
 
Figure 1. Potential applications for human ESCs in clinic and research. 
Embryonic stem cells can be used as sources of differentiated cells for scientific 
research, drug testing and transplantation therapy. They can also be used to study 
early developmental processes and genetic diseases. Additional applications for 
hESCs could still be developed in the future. Reprinted from the Virtual Genetics 
Education Centre, Department of Genetics, University of Leicester 
(http://www2.le.ac.uk/departments/genetics/genie/gs/law/lawembryonic) under 
Creative Commons License. 
  4 
 
developed, including the very promising technique of factor-based reprogramming, 
which derives induced pluripotent stem cells from somatic cells (Takahashi et al., 
2007; Takahashi and Yamanaka, 2006). 
 However, regardless of source, human pluripotent cells have to overcome the 
major hurdle of efficient directed differentiation. Despite the availability of a plethora 
of published differentiation protocols (Tabar and Studer, 2014), most do not provide a 
differentiation efficiency of 100%, which raises concerns on safety due to the risk of 
teratoma formation (Ben-David and Benvenisty, 2011). This also poses practical 
problems, as the application of hESCs in regenerative medicine often requires access 
to unlimited numbers of pure and functional populations of specific cell types. Thus, a 
prerequisite for the clinical application of hESCs is an improved understanding of 
their differentiation, which includes the initial exit from pluripotency (which we 
discuss in detail in this thesis) and all intermediate steps before the cell commits to its 
terminal differentiated fate. 
 
C. Defining features of hESCs 
To date, hundreds of hESC lines have been derived, necessitating the 
establishment of the integrity of hESC lines for further downstream use. First of all, 
hESCs must exhibit basic characteristics including a normal karyotype, indefinite 
proliferation in vitro and recovery from freeze-thaw cycles (Brivanlou et al., 2003).   
In culture, hESCs should form flat, compact colonies, in contrast to the more 
disperse morphologies of their differentiated counterparts. hESCs must also exhibit 
the unique expression profile landmarked by the high expression of pluripotency-
specific markers including POU5F1, NANOG, SOX2, TDGF1 and PRDM14 (Assou 
et al., 2007). hESCs are also characterized by the expression of cell-surface markers 
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such as TRA-1-60, TRA-1-81, SSEA3 and SSEA4, and the presence of alkaline 
phosphatase activity (Thomson et al., 1998) .  
On top of possessing these molecular signatures, hESCs must have the 
capability to differentiate into cells from the three major embryonic germ layers in 
vitro and in vivo. This can be measured using directed differentiation protocols, 
embryoid body formation assays or teratoma formation assays. Fulfilment of all these 
characteristics ensures bona fide hESC identity. 
 
II. Maintenance of the human pluripotent state 
The maintenance of ESCs in vitro is made possible by manipulating the 
extrinsic signalling environment, which integrates into the intrinsic transcriptional 
circuitry of cells. Given the correct conditions, proper signalling events can sustain 
the transcriptional program of pluripotency, allowing the undifferentiated self-renewal 
of ESCs. 
 
A. Regulatory network of hESCs 
The sustenance of human pluripotency is mediated by an intricate regulatory 
network chiefly controlled by a few transcription factors, mainly the triumvirate of 
OCT4, SOX2 and NANOG (Boyer et al., 2005). These master regulators form 
multiple regulatory connections with one another (Figure 2A), with secondary 
transcription factors, and with other effectors such as epigenetic modifiers, 
transduction pathways and non-coding RNAs that together maintain self-renewal and 
pluripotency (Figure 2B) (Loh et al., 2011; Ng and Surani, 2011; Young, 2011; Yu 
and Thomson, 2008).  




B. Signalling control of hESC maintenance 
Sustenance of the pluripotency network is dependent on the extrinsic 
environment, and is held together by a specific set of external signals. hESCs were 
initially cultured in the presence of mitotically-inactivated fibroblast feeders, which 
provided these signalling factors that were important for hESC maintenance 
(Thomson et al., 1998). Conditioning culture medium with feeders (widely known as 
‘conditioned medium’) allowed an easy alternative to provide such external signalling 
Figure 2. Regulatory network of hESCs. (A) OCT4, SOX2 and NANOG form 
multiple auto-regulatory loops that stabilize the core hESC transcriptional 
network. (B) OCT4, SOX2 and NANOG act on multiple downstream elements to 
promote pluripotency. Reprinted from Cell 122, Boyer, L.A. et al. Core 
transcriptional regulatory circuitry in human embryonic stem cells, 947-956, 
Copyright (2005), with permission from Elsevier. 
  7 
 
molecules in the absence of feeder cells. However, a requirement for defined hESC 
culture conditions called for efforts to dissect signalling control of hESC maintenance. 
This led to the identification of basic fibroblast growth factor (bFGF) and 
Activin/transforming growth factor beta (TGF-β) as the most critical signalling 
molecules for hESC cultivation (Beattie et al., 2005; Ludwig et al., 2006; Xu et al., 
2005). Using this knowledge, chemically-defined media such as mTeSR1 (Ludwig 
and Thomson, 2007) and Essential 8 (Chen et al., 2011) have been designed for hESC 
maintenance. 
The action of the bFGF pathway in pluripotency has largely been attributed to 
the downstream MEK-ERK cascade, which inhibits upregulation of neural 
specification genes (Greber et al., 2011; Li et al., 2007). In addition, the bFGF 
pathway has been attributed to promote pluripotency through pleiotropic effects 
including enhancing hESC proliferation, attachment and survival (Eiselleova et al., 
2009; Wang et al., 2009). The TGFβ signalling pathway functions by activating 
ALK4 activity through its receptor, which in turn activates the downstream effector 
SMAD2/3. Upon activation and dimerization, SMAD2/3 binds the NANOG proximal 
promoter and upregulates NANOG expression, among other pluripotency genes, in 
hESCs (Vallier et al., 2009; Xu et al., 2008). Moreover, both the TGFβ and bFGF 
signalling pathways antagonize the BMP4 signalling pathway, which acts to repress 
pluripotency genes through its effectors SMAD1/5/8 (Xu et al., 2008). 
It is also important to acknowledge that besides the major governance by the 
bFGF-MEK and TGFβ pathways, other signalling pathways also contribute to the 
human pluripotent state. bFGF and additional factors found in human pluripotency 
media such as insulin-like growth factor activate the phosphoinositide-3-kinase 
(PI3K) signalling pathway, which in turn cooperates with both the TGFβ pathway and 
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the bFGF-MEK axis to promote pluripotency (Bendall et al., 2007; McLean et al., 
2007; Singh et al., 2012). In addition, the Wnt signalling pathway has been implicated 
to promote hESC maintenance (Sato et al., 2004), although its function appears to be 
highly context-dependent (Cai et al., 2007; Davidson et al., 2012; Dravid et al., 2005).  
A precise understanding of how exactly these pathways interact to regulate 
pluripotency has not been achieved due to several confounding factors including the 
use of various and often disparate culture conditions and experimental designs, and 
the tendency to zoom in onto a specific pathway with a lack of consideration for its 
integration with other pathways. Nonetheless, it is clear that the cross-talk between 






Figure 3. Signalling pathways governing hESC self-renewal. The bFGF 
(FGF2), PI3K and TGFβ (Activin/Nodal) pathways promote maintenance of 
hESCs, while the BMP4 pathway promotes differentiation. Reprinted by 
permission from Macmillan Publishers Ltd: Gene Therapy (Ohtsuka, S. and 
Dalton, S., Molecular and biological properties of pluripotent embryonic stem 
Cells), copyright (2007).  
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III. High-throughput RNA interference screening in ESCs 
Many studies on the maintenance of pluripotency have utilized a plethora of 
research technologies to prove the importance of certain factors in keeping the ESC 
state. Among these, the method of knocking down gene expression using RNA 
interference (RNAi) has immensely contributed to the search for crucial players in the 
regulation of the ESC state.  
 
A. Biology of RNAi technology 
The method of delivering RNA to silence specific genes (Figure 4) was first 
demonstrated by Mello and colleagues in 1998 using the model system 
Caenorhabditis elegans (Fire et al., 1998). It was shown that injection of double-
stranded RNA (dsRNA) into the nematode can potently and specifically suppress 
gene expression in the animal and its progeny. Subsequent studies discovered that a 
ribonuclease III enzyme, now known as Dicer, cleaves RNAi-inducing dsRNA into 
21 to 22-nucleotide short interfering RNA (siRNA) (Bernstein et al., 2001; Elbashir et 
al., 2001b; Hammond et al., 2000; Zamore et al., 2000). The siRNA recruits the RNA-
induced silencing complex (RISC), and together, they post-transcriptionally attenuate 
gene expression by binding to the target messenger RNA (mRNA) (Hammond et al., 
2000; Zamore et al., 2000). While the siRNA confers sequence specificity to its target 
mRNA by perfect complementation, the RISC is the effector of gene silencing by 
recruiting nucleases like the Argonaute proteins for mRNA degradation. The utility of 
siRNAs in gene silencing extends from C. elegans to cells of higher animals including 
insects, lower mammals and humans (Caplen et al., 2000; Clemens et al., 2000; 
Elbashir et al., 2001a; Hammond et al., 2000; Ui-Tei et al., 2000). Since then, siRNAs 
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have become a robust tool in biological research to systematically shut down 
expression of genes of interest, as it conveniently bypasses the generation of 
genetically-modified cells or animals.  
 
 
Figure 4. Mechanisms of RNAi in mammalian cells. dsRNA is cleaved by 
Dicer into siRNA, which associates with the RISC. AGO2 in the RISC catalyzes 
the cleavage of the mRNA complementary to the siRNA. siRNA are also 
postulated to silence transcription in the nucleus. Reprinted by permission from 
Macmillan Publishers Ltd: Nat Rev Genet (Kim, D. and Rossi J., Strategies for 
silencing human disease using RNA interference), copyright (2007).  
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B. High throughput RNAi screening 
In the recent years, technological advances have facilitated the execution and 
analysis of biological assays in a high-throughput manner. The practicality of RNAi 
has propelled it to be at the forefront of high-throughput assays by enabling 
systematic loss-of-function screening. The application of reliable sequencing data to 
RNAi technology has made it possible to build libraries of RNAi reagents for high-
throughput applications (Carpenter and Sabatini, 2004). This extended functional 
analyses that was only pragmatic for small sets of samples to a colossal number of 
samples observed in parallel, making it a powerful tool for cell biology. In addition, it 
can be used in combination with other assays or treatments (known as modifier 
screens), making it a method of choice for dissecting specific processes or pathways 
and for the development of therapeutic agents (Echeverri and Perrimon, 2006).  
While RNAi screening has many advantages, this comes at the price of the 
equally numerous parameters that one needs to consider when conducting such 
experiments (Figure 5) (Sharma and Rao, 2009). These include: (1) choosing whether 
to do a genome-wide screen or focus on a subset of specific annotated genes, (2) 
selecting a cellular system to be used to answer a particular biological question, (3) 
deciding whether to pool all RNAi constructs and perform subsequent sequencing or 
to individually knockdown genes in an arrayed format, and (4) developing an 
appropriate and robust readout assay for hit identification. Furthermore, technical 
details such as the method of RNAi delivery, addition of reliable controls, inclusion of 
additional filters to eliminate false positives, and application of the appropriate 
statistical methods for normalization also have to be carefully deliberated. 
 





Figure 5. Considerations for high-throughput RNAi screening. The process of 
designing a high-throughput RNAi experiment encompasses multiple decision-
making and technical steps, all of which need to be executed correctly for the 
success of the experiment. Reprinted by permission from Macmillan Publishers 
Ltd: Nat Immunol (Sharma, S. and Rao A., RNAi screening: tips and techniques), 
copyright (2009). 
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Designing a high-throughput assay is greatly dependent on the biological 
question of interest. Once the proper decisions have been made, high-throughput 
RNAi screening can be a very powerful discovery tool for both general biological 
processes and more specific pathways. 
 
C. High-throughput RNAi screens in ESCs 
Given the utility of high-throughput RNAi screening, it did not take long 
before the technique was applied in the context of pluripotency. The first research 
utilizing this technology to study the regulation of pluripotency was in mouse ESCs 
(mESCs) (Ivanova et al., 2006). This study revealed the importance for mESC self-
renewal of Tbx3, Tcl1 and Esrrb, which acted together in a functional network 
distinct from the Oct4-Sox2-Nanog cluster (Ivanova et al., 2006). Thereafter, several 
RNAi screens have been performed, discovering various novel factors and complexes 
important for mESCs, such as the Paf1 complex (Ding et al., 2009), Cnot3 and 
Trim28 of the c-Myc cluster (Hu et al., 2009), and the mediator and cohesin 
complexes (Kagey et al., 2010).  
A similar strategy of high-throughput RNAi screening has been adopted in 
hESCs to uncover regulators of maintenance of the pluripotent state in the human 
system (Chia et al., 2010). Using this approach, new factors such as PRDM14, 
NFRKB, the INO80 complex and the COP9 complex have been identified to play a 
role in hESCs. Moreover, dissimilarities in the pluripotency transcriptional circuitry 
between the mouse and human species were revealed in this study, highlighting the 
importance of species-specific differences in the network regulating pluripotency. 
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The various studies described above demonstrate the success of high-
throughput RNAi screening in interrogating noteworthy biological questions, 
including that of pluripotency. The findings from these studies collectively reaffirm 
the concepts of multifaceted regulation of complex processes such as the maintenance 
of pluripotency, and the interdependence of regulatory functions between various 
pathways and complexes. More importantly, this platform enabled the identification 
of novel factors and pathways crucial for the regulation of the pluripotent state.   
 
IV. The exit from pluripotency 
Through genome-wide RNAi screens and many other molecular tools that are 
available today, the regulation of pluripotency and the factors governing the self-
renewing state of ESCs is relatively well-defined. However, the maintenance of 
pluripotency is only one side of the coin; ESC fate is determined by a balance 
between ESC maintenance and differentiation signals from the cell culture 
environment (Loh et al., 2011; Ng and Surani, 2011; Young, 2011; Yu and Thomson, 
2008). A loss of ESC maintenance signals or dominance of differentiation signals can 
initiate the process of differentiation by driving stem cells out of the pluripotent ESC 
state (Figure 6). During this process, transcriptional networks conferring ESC identity 
need to be shut down and subsequently, lineages have to be determined. While many 
studies have identified factors for the maintenance of pluripotency and also for the 
determination of specific cell fates, the knowledge on the machinery behind the 
initiation of exit from the pluripotent state is scarce.  





It is important to clarify that the exit from pluripotency is a distinct 
phenomenon from lineage specification (Figure 6). Whereas lineage specification 
marks the activation of the transcriptional program of a particular cell fate, the exit 
from pluripotency is defined here by the shutting down of the ESC program. It is 
important to understand the system that maintains the pluripotent state in order to 
fully harness the potential of ESCs in research and medicine, as cultivation of high-
quality ESCs in large quantities is ideal for the mass production of specialized tissues. 
However, it is equally imperative to learn about the system that pushes ESCs out of 
Figure 6. The process of differentiation. In the absence of self-renewal signals 
or in the presence of differentiation signals, ESCs undergo differentiation. This 
process starts with the exit from pluripotency, characterized by the shutdown of 
the pluripotency network. Cells then acquire a new transcriptional program in the 
process of lineage specification. 
  16 
 
the pluripotent state and enables them to adopt a new program of their chosen lineage, 
as most applications of hESCs require precise control of their differentiation into 
specific somatic cell types. 
The intrinsic and extrinsic signals regulating the maintenance of the ESC state 
in vitro are reasonably established. Using this knowledge, the machinery responsible 
for the exit from the pluripotent state can be studied by pushing ESCs out of self-
renewal. This can be done by removal of essential growth factors, disruption of the 
transcriptional circuitry sustaining pluripotency or addition of differentiation inducers. 
These techniques have been applied in mESCs to identify currently known factors 
involved in the exit from pluripotency, including Tcf3 (Cole et al., 2008; Guo et al., 
2011), Mp1 (Westerman et al., 2011), Dgcr8 (Wang et al., 2007), Dicer 
(Kanellopoulou et al., 2005), Dpy30 (Jiang et al., 2011), Jarid/Jumonji (Peng et al., 
2009) and Spi1 (Abujarour et al., 2010).  
RNAi screening has also been applied to study this question by Smith and 
colleagues on mESCs (Betschinger et al., 2013). In their study, they discovered that 
factors involved in the export of the transcription factor Tfe3 from the nucleus are 
essential for the exit from pluripotency. They similarly explored the regulation of exit 
from pluripotency in haploid mESCs through a piggyBac mutagenesis approach (Leeb 
et al., 2014), and identified a role for Zfp706 and Pum1 in the exit from pluripotency. 
These high-throughput studies not only reveal multiple levels of regulation in the exit 
from pluripotency, but also provide a great resource for future examination of mESC 
differentiation. 
However, these studies have investigated the exit from pluripotency only in 
the context of mESCs, and no similar study has been conducted in hESCs to the best 
of our knowledge. Given that the regulation of pluripotency in mESCs is very distinct 
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from hESCs (Gonzales and Ng, 2011; Hanna et al., 2010; Nichols and Smith, 2009), 
studies conducted on hESCs are necessary to obtain accurate knowledge about how 
the hESC regulatory network is shut down for complete and efficient differentiation to 
occur; this gap in knowledge is addressed in this thesis. 
 
V. The cell cycle in pluripotency 
Cell division requires the replication of the DNA blueprint, followed by the 
segregation of the replicated chromosomes into the two daughter cells. This requires 
elaborate coordination of many processes ultimately governed by the cell cycle. The 
cell cycle is divided into four phases: the S phase wherein DNA replication occurs, 
the M phase wherein cellular division happens, and the two gap phases wherein cells 
prepare all necessities before the S and M phases (Vermeulen et al., 2003).  
 
A. Regulation of cell cycle progression 
The key regulatory proteins that govern cell cycle progression are cyclins and 
their interacting cyclin-dependent kinases (CDKs), with different CDKs active during 
each cell cycle phase (Figure 7). While CDK protein levels are stable across the cell 
cycle, their activity is controlled by their specific partner cyclins, whose protein levels 
rise and fall during the course of the cell cycle. Cyclin D is required for progression 
through the G1 phase by activating CDK4/6 activity (Sherr, 1994). Cyclin E peaks 
during the G1/S transition, activating CDK2 for entry to the S phase (Ohtsubo et al., 
1995). Cyclin A expression increases at the S phase when it partners with CDK2, and 
persists until entry into mitosis when it partners with CDK1 (Girard et al., 1991; 
Walker and Maller, 1991). CDK1 activity is also enhanced by Cyclin B expression 
which peaks at the G2/M transition (King et al., 1994).  






In addition to the periodic activities of CDKs, progression through the cell 
cycle is gated by multiple checkpoints that ensure that all required processes are in 
place and the integrity of the cell and its DNA are intact before proceeding onto the 
next phase (Figure 7). These checkpoints are activated in the presence of stressors and 
act upstream of the CDKs to halt cell cycle progression. The G1/S checkpoint mainly 
halts cell cycle progression through the activity of tumor suppressors Rb (which 
 
Figure 7. The cell cycle and its checkpoints. The cell cycle is divided into 4 
phases. Progression through these phases is driven by various Cyclin-CDK 
complexes. Each phase has a checkpoint wherein cell cycle progression can be 
halted in case an error is detected.  
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controls the restriction point), p21 and p53 (Kastan and Bartek, 2004).  The intra-S 
checkpoint acts through the ATM/ATR signalling pathway to halt DNA replication 
(Bartek et al., 2004). The G2/M checkpoint targets multiple pathways leading to 
Cyclin B/CDK1 inhibition to prevent entry into mitosis (Kastan and Bartek, 2004). 
Finally, the metaphase checkpoint has unattached kinetochores signalling to the 
anaphase promoting complex to prevent initiation of anaphase (Lara-Gonzalez et al., 
2012). Together, these checkpoints ensure that every round of the cell cycle is 
completed without error. 
 
B. Influence of the cell cycle on biological processes 
 During the cell cycle, cells undergo dramatic physical and biochemical 
changes, engendering different cell states. These cell states are found to influence 
cellular decisions in perspectives other than proliferation such as metabolism and 
inflammatory responses. For example, studies in yeast have discovered that enzymes 
involved in glycolysis, oxidative phosphorylation, fatty acid biosynthesis were all 
induced during the G1 phase of the cell cycle (Cho et al., 1998). Research on human 
fibroblasts demonstrated that the replication checkpoint can activate inflammatory 
responses by inducing interleukin-6 secretion (Rodier et al., 2009). In mESCs, the 
physical state of DNA during replication was found to promote cell fate changes after 
nuclear fusion with somatic cells (Tsubouchi et al., 2013), while shortened telomeres 
were found to block fate transitions (Pucci et al., 2013). These findings provide 
evidence that cells have evolved to utilize cell cycle states in order to prime and 
regulate other biological events, which may include pluripotency.  
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C. Cell cycle of ESCs 
Given the importance of the cell cycle, its regulation and progression is widely 
conserved across animal species and cell types. However, unlike most cells, in vivo 
pluripotent stem cells participate in rapid and uninterrupted symmetric cell divisions 
prior to gastrulation (Edgar and Lehner, 1996; Lawson et al., 1991; Murray and 
Kirschner, 1989; Yarden and Geiger, 1996), in order to quickly amplify up to cell 
numbers required for early embryonic development. Their extraordinary speed in cell 
division is enabled by a unique cell cycle profile featuring alternating rounds of DNA 
synthesis (S phase) and mitosis (M phase) with very short or no interjecting gap 
phases.  
Interestingly, this unique cell cycle profile is preserved in ESCs in vitro 
(Figure 8A). Both mouse and human ESCs spend the majority of their time in the S 
and G2 phases, while the length of the G1 phase is drastically shortened compared to 
their somatic counterparts (Coronado et al., 2013; Hindley and Philpott, 2013; Singh 
and Dalton, 2009; Stead et al., 2002). Accordingly, the differentiation of hESCs 
reverts their cell cycle profile by the lengthening of the G1 phase (Calder et al., 2013; 
Filipczyk et al., 2007), potentially facilitated by the increase in negative regulators of 
proliferation, such as p21 and p27, during the differentiation of hESCs (Egozi et al., 
2007). This abbreviation of the G1 phase is very specific to the pluripotent state, and 
this is because the hESC pluripotency network is responsible for enforcing it (Figure 
8B). For example, OCT4, SOX2 and MYC all promote expression of miRNAs such 
as miR-302 (Card et al., 2008; Judson et al., 2009; Singh and Dalton, 2009), which 
belong to the class known as ESC cycle (ESCC) miRNAs, which specifically promote 
the G1-to-S transition in ESCs. NANOG on the other hand promotes expression of 
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CDK6 and CDC25A to facilitate S phase entry of hESCs (Zhang et al., 2009). Hence, 
cell cycle regulation by the transcriptional program intrinsic to pluripotency couples 





Figure 8. The cell cycle profile of ESCs. (A) A smaller proportion of ESCs 
spend their time in the G1 phase compared to somatic cells. A larger proportion of 
ESCs are instead in the S phase. Reprinted from Cell Stem Cell 5, Singh, A.M. 
and Dalton, S. The cell cycle and Myc intersect with mechanisms that regulate 
pluripotency and reprogramming, 141-149, Copyright (2009), with permission 
from Elsevier. (B) Pluripotency-associated transcription factors promote 
transcription of genes that facilitate the G1-to-S transition. 
  22 
 
D. Regulation of the exit from pluripotency by the cell cycle machinery  
While the pluripotency network acts to facilitate the unusual cell cycle profile 
of ESCs, this in turn is believed to contribute to the maintenance of pluripotency. 
First, ESCs are characterized by a globally euchromatic genome (Gaspar-Maia et al., 
2011; Meshorer et al., 2006), which is important for their ability to give rise to the 
various cell types of the embryo, as it facilitates rapid epigenetic changes in response 
to differentiation cues. The accelerated G1-to-S transition displayed by ESCs could 
help maintain this open chromatin state, as experimentally observed in Rb-deficient 
fibroblasts (Herrera et al., 1996). Second, and perhaps more importantly, the current 
paradigm dictates that G1 is the only phase permissive to differentiation (Mummery et 
al., 1987; Pauklin and Vallier, 2013; Sela et al., 2012), and the shortening of this 
phase in ESCs serves to minimize aberrant exit from pluripotency.  
The window of opportunity for differentiation provided by the G1 phase in 
hESCs can potentially be explained by three varying but non-exclusive hypotheses. 
First, the G1 phase boasts an enrichment of cell cycle factors like CDK inhibitors and 
Cyclin D that contribute to lineage specification (Li et al., 2012a; Pauklin and Vallier, 
2013). Second, the state of chromatin modifications in the G1 phase, such as elevated 
5-hydroxymethylcytosine levels, leads to higher expression of differentiation markers 
(Singh et al., 2013) that lowers the differentiation threshold. Third, the displacement 
of transcription factors in the M phase (Martinez-Balbas et al., 1995) creates a blank 
slate for establishing new transcriptional programs in the G1 phase (Egli et al., 2008). 
However, none of these hypotheses have been compellingly proven as studies on the 
regulation of pluripotency by the cell cycle in hESCs are mostly limited to correlation. 
Hence, there is no direct evidence hitherto that factors within the core cell cycle 
machinery deterministically control the maintenance of or the exit from pluripotency. 
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How ESCs make their fate choices in response to cell cycle events have direct 
consequences on genome stability, tissue development and stem cell maintenance. 
Therefore, it is imperative to interrogate the functional relationships between the cell 








In this thesis project, we aimed to search for factors crucial for the exit from 
the human pluripotent state. We did this by developing a systematic approach that 
capitalizes on the investigative strength of high-throughput RNAi screening and 
applied it to hESCs to study the exit from pluripotency. We found multiple processes 
that regulate the exit from pluripotency, which encompass those that function in a 
context-dependent manner and those which are universally important for the exit from 
pluripotency. These pathways range from histone acetylation and chromatin 
remodelling to development-related signalling, showcasing that control of the exit 
from pluripotency occurs in a diverse fashion at multiple levels.  
Importantly, we found that the cell cycle has an assertive effect on the exit 
from pluripotency, as the exit from pluripotency is blocked upon cell cycle arrest at 
the S and G2 phases. Therefore, we additionally aimed to find mechanisms by which 
the exit from pluripotency becomes hard-wired to the cell cycle machinery. We found 
that cell cycle pathways stimulated during S and G2 phase perturbation play an active 
role in promoting the pluripotent state and preventing its exit. Thus, this thesis 
addresses the unanswered question of whether factors in the core cell cycle machinery 
enforce a deterministic regulation on pluripotency and differentiation in ESCs.   
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Materials and Methods 
 
Cell Culture 
The hESC lines H1 (WA-01, passage 30), NANOG-GFP H1 reporter cells 
(passage 50) and ACTIN-GFP H1 reporter cells (passage 45) were used for this study. 
They were cultured feeder-free on Matrigel (BD) with mTeSR1 medium 
(STEMCELL Technologies). Medium was changed daily. The hESCs were routinely 
subcultured with 1 U/mL Dispase in DMEM:F12 (STEMCELL Technologies) every 
4–5 days. For experiments, hESCs were passaged using TrypLE™ Express (Life 
Technologies) before treatment. 
For treatment with small molecules, chemicals diluted in DMSO were added 
to cell culture medium to achieve 0.2% DMSO by volume. The compounds used are 
as follows: PD0332991 (6 μM, Santa Cruz), Aphidicolin (75 ng/mL, Sigma), 5-
hydroxyurea (0.2 mM, Sigma), Alisertib (65 nM, Selleckchem), RO3306 (10 μM, 
Enzo Life Science), Nocodazole (18 ng/mL, SciMed), Barasertib (50 nM, 
Selleckchem), BI2539 (5.5 nM, Selleckchem), Taxol (1.1 nM, Santa Cruz), Caffeine 
(1 mM, Sigma), AZD7762 (100 nM, Selleckchem), Nutlin (4uM, Cayman Chemical). 
 
Reporter Line Generation 
EGFP cassette with kanamycin selection was inserted into BACs for NANOG 
(CTD-2317D19, BacPac) and beta-Actin (CTD-3223H20, BacPac) immediately 
before the initiating Methionine (ATG) of respective genes using recombineering 
(Quick & Easy BAC Modification Kit, KD-001, Gene Bridges GmbH). The Tol2 
transposon cassette with Ampicillin selection mark was inserted into the loxP site of 
the BAC in the backbone using recombineering. 10 million H1 cells were cultured in 
  26 
 
CF1 conditioned medium (20% KO serum replacement, 1 mM l-glutamine, 1% non-
essential amino acids, 0.1 mM 2-mercaptoethanol and 8 ng ml−1 of basic fibroblast 
growth factor in DMEM:F12) for 6 days and dissociated into single cells with 
TrypLE™ Express (Life Technologies) and electroporated with 20 micrograms of 
Tol2 transposes and 100 micrograms of Tol2/EGFP modified Transposon-BACs. 
After electroporation, the cells were resuspended in conditioned medium with 10 μM 
ROCK inhibitor Y27632 (Calbiochem). Rock inhibitor was added for the first 48 
hours after electroporation. 50 micrograms/ml geneticin (Gibco) was added for 
selection of positive clones 72 hours post-electroporation. 14 days later after drug 
selection, single colonies were picked into 24 well plates for expansion. Fluorescent 
in situ hybridyzation (FISH) using non-modified BACs as probes was carried out to 
validate the incorporation of BAC construct into genome of ES cells (Cytogenetics 
Services, Genome Institute of Singapore).  
 
High-throughput RNAi screening for the exit from pluripotency 
384-well plates (Greiner) were coated with 10 uL of 30x-diluted Matrigel 
(BD) overnight before removing excess Matrigel. Pooled siRNAs (2.5 uL of 1 μM; 
Dharmacon, Ambion) were printed on the plates and frozen at -80°C before use. 
Reverse transfection was performed by adding a master mix of Lipofectamine RNAi 
Max (Invitrogen) diluted 200x in 5 uL OptiMEM (Invitrogen) per well, and incubated 
at room temperature for 20 mins. 45 uL mTeSR1 (STEMCELL Technologies) 
containing approximately 3,000 NANOG-GFP H1 hESCs were seeded as single cells 
with 500 nM Thiazovivin (Tocris). mTeSR was replaced with differentiation media 
24hrs after seeding. The differentiation media used are as follows: 1) - bFGF, -TGFβ 
condition: mTeSR1 without select growth factors (STEMCELL Technologies), 
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namely bFGF, TGFβ, GABA and pipecolic acid, 2) TGFβ pathway inhibition: 
mTeSR + 1 μM A8301 (Stemolecule), 3) bFGF pathway inhibition: mTeSR1 + 2.5 
μM PD0325901 (Sigma), 4) + Retinoic acid: mTeSR1 + 20 μM retinoic acid (Sigma). 
Cells were incubated in differentiation media for 120hrs for condition 1, and 48 hrs 
for conditions 2, 3 and 4. Media were then replaced with mTeSR1 and incubated for 
another 48 hrs to enrich for pluripotent cells. The cells were then fixed with 4% 
paraformaldehyde (Sigma) for 30 mins, and then stained with Hoechst 3342 (1:4000, 
Invitrogen) in 1% Triton X-100 for 30 mins. GFP fluorescence microscope photos 
were acquired using ImageXpress Ultra (Research Instruments) at 20x magnification 
with 9 pictures taken per well, and quantified using MetaXpress Image Acquisition 
and Analysis software. z-score was calculated using the formula z = (X − µ)/s.d. where 
µ is the mean and s.d. is the standard deviation of the whole population. X is the 
sample value calculated based on the integrated fluorescent intensity divided by total 
number of cells. Cell viability scores were calculated using the formula v = Cs/Cnt 
where Cs is the total number of cells in the sample well and Cnt is the mean total 
number of cells in the negative control wells in the same plate. The Z′ factors for all 
screens are > 0.5. Screen analyses was done using Screensifter software(Kumar et al., 
2013). 
  
Informatics analysis for screen results 
For individual analyses, genes considered hits have z > 1.25 or z > 1.5 (above 
noise) in at least 2 out of 3 replicates for each condition. For the combined analysis, 
genes considered hits have z > 1.25 in at least 4 out of 9 sets in - bFGF, - TGFβ, 
TGFβ pathway inhibition and bFGF pathway inhibition conditions. Hits which also 
have z > 1.5 in at least 2 out of 3 replicates in + Retinoic acid condition are excluded 
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in the combined analysis. For the ACTIN-GFP H1 RNAi screens, genes considered 
hits have z > 1.25 in both replicates. For the analysis of hits that enhance the exit from 
pluripotency, genes considered hits have z < -1, -1.25 or -1.5 in at least 2 out of 3 
replicates for each condition. List of hits for the - bFGF, - TGFβ, TGFβ pathway 
inhibition and bFGF pathway inhibition conditions were pooled for combined 
analysis. 
Hierarchical clustering of screen conditions was performed by calculating 
Euclidian distances between the set of z-scores from each condition using the distance 
matrix algorithm in R. Gene ontology analysis was performed with DAVID functional 
annotation tool (david.abcc.ncifcrf.gov) for biological processes and functional 
clusters. Reactome pathway analysis was performed at www.reactome.org was used 
for the analysis of reactions and/or pathways that were statistically over-represented 
from the hits. Protein-protein interaction network was generated using STRING 
database (string.embl.de), and filtered only for experimentally-validated interactions. 
The resulting network was imported into Cytoscape (www.cytoscape.org), and then 
HPRD (www.hprd.org) validated interactions were added to the network. Enriched 
clusters were derived using Markov clustering algorithm (Van Dongen, 2008).   
 
RNA quantification and RT-qPCR 
RNA was extracted from cells using TRIzol® (Invitrogen). 500 ng RNA was 
reverse-transcribed using Superscript II (Invitrogen) utilizing the oligo(dT) primer. 
mRNA expression changes were quantified from qPCR using SYBR Green (KAPA). 
Measured transcripts were normalized to GAPDH and all samples were run in 
triplicate. qPCR primer sequences used are available in Appendix 1.  
 




Knockdown of gene expression with RNAi constructs 
Knockdowns were performed using shRNAs designed using BLOCK-iT 
RNAi designer (Invitrogen) cloned into the pLKO.1 vector. pLKO.1 lentiviruses were 
packaged using HEK293T cells. 2 uL of concentrated viruses was added to culture 
medium with 4 ug/mL polybrene (Sigma). Knockdowns were also performed using 
siRNAs (Bioneer) at a final concentration of 50 nM transfected using Lipofectamine 
RNAi Max (Invitrogen). A full list of sequences of RNAi constructs used in this 
thesis can be found in Appendix 2. 
 
Immunoblotting 
Immunoblotting was performed as conventional procedures using cells lysed 
with RIPA buffer with proteinase inhibitor (Merck). Antibodies against Cyclin D 
(AF4196, 1:200), Cyclin E (AF6810, 1:200), Cyclin A2 (AF5999, R&D system 
1:1000), Cyclin B1 (sc-245, Santa Cruz, 1:500), p53 (sc-126, Santa Cruz, 1:500), p21 
(sc-397, Santa Cruz, 1:500), pChk1 (2348, Cell Signalling, 1:1000),  pChk2 (2661, 
Cell Signalling, 1:1000), pSmad2 (3108, Cell Signalling, 1:500) and Glyceraldehyde 
3-phosphate dehydrogenase (sc-25778, 1:1000) were used.  
 
Immunostaining, microscopy and FACS 
To perform OCT4, NANOG, TRA-1-60 and TRA-1-81 immunostaining for 
microscopy, cells were fixed with 4% formaldehyde (Sigma) on tissue culture plates 
(Falcon) and permeabilized using 1% Triton X-100. Primary antibodies used are as 
follows: OCT4 (ab19857, Abcam, 1:5000), NANOG (AF1997, R&D system, 500 
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ng/mL), TRA-1-60 (sc-21705, Santa Cruz, 1:500), TRA-1-81 (sc-21706, Santa Cruz, 
1:500), p53 (sc-126, Santa Cruz, 1:500). To perform γH2AX immunostaining for 
microscopy, cells were harvested by cytospinning, fixed with 4% formaldehyde 
(Sigma) and stained with antibody against γH2AX (#2577, Cell Signalling, 1:800). 
Secondary antibodies used were Alexa Fluor 488 anti-mouse IgG, Alexa Fluor 488 
anti-rabbit IgG, and Alexa Fluor 546 anti-goat IgG (Invitrogen). Hoechst 3342 
(1:4000, Invitrogen) was used for nuclear staining. All microscope images were taken 
using Observer Z.1 (Zeiss). 
To perform immunostaining for FACS, cells were harvested, fixed with 4% 
formaldehyde (Sigma) and 80% ethanol. To obtain cell cycle profiles, cells were 
stained with antibody against phospho-histone H3 (06-570, Merck, 1:1000) and 
Hoechst 33342. FACS analyses were done using LSRII flow cytometer (BD).  
 
Microarray analysis 
mRNAs derived from hESCs were reverse transcribed, labelled and analyzed 
on Illumina microarray platform (HumanHT-12 v4 Expression BeadChips). Arrays 
were processed according to manufacturer’s instructions. Biological triplicate 
microarray data were generated. Rank invariant normalization was used to normalize 
the microarrays. SAM (statweb.stanford.edu/~tibs/SAM) was used for analysis and 
matrix2png (www.chibi.ubc.ca/matrix2png) for visualization. 
 
Teratoma assay 
hESCs were dissociated with TrypLE™ Express (Life Technologies) and 
resuspended in Matrigel (BD) diluted 3x in DMEM:F12 (Nacalai Tesque) at a 
concentration of 1,000,000 cells/mL. 100uL of the cell suspension was injected into 
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the dorsal flanks of BALB/c nude mice anesthetized with isoflurane. After 6-8 weeks, 
teratomas were harvested, surgically dissected, fixed in Bouin’s solution, embedded 




hESCs were treated with colcemid to induce mitotic arrest. Cells were then 
harvested by standard hypotonic treatment and methanol:acetic acid (3:1 v/v) fixation. 
Slides were prepared by standard air drying and G-band karyotyping was executed.  
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Results and Discussion 
 
I. The high-throughput RNAi screening conditions are optimized to assay for the exit 
from pluripotency 
With the aim of uncovering factors and processes that are required for the exit 
from pluripotency, we designed a high-throughput RNAi screen in hESCs under 
multiple differentiation conditions. To ensure the robustness of the experimental 
design, initial optimization experiments were performed as follows. 
 
A. Search for a reliable marker of the pluripotent state 
To perform a high-throughput assay for the exit from pluripotency, we needed 
a reliable marker with an expression that changes rapidly and drastically upon 
induction of differentiation. We triggered the exit from pluripotency of hESCs 
through the withdrawal of bFGF and TGFβ (- bFGF, - TGFβ condition), as these two 
factors are necessary for hESC self-renewal (Beattie et al., 2005; Ludwig et al., 2006; 
Xu et al., 2005). The expression profiles of an array of genes which are known to 
have differential expression in hESCs and somatic cells (Assou et al., 2007) were then 
compared at 0, 48 and 96 hours of incubation in - bFGF, - TGFβ (Figure 9). We found 
that some genes like GPC4 and INDO undergo a transient upregulation upon exit 
from pluripotency; these are not suitable markers for the pluripotent state. Conversely, 
majority of the genes showed a gradual decrease in expression in - bFGF, - TGFβ. 
Among these, NANOG showed the greatest decrease in expression at both the earlier 
and later time points. Thus, we chose NANOG as the ideal marker for the human 
pluripotent state, as it provides the most rapid and drastic decrease in expression upon 
induction of the exit from pluripotency. 






B. Generation and validation of the NANOG-GFP hESC line  
To easily monitor NANOG expression of hESCs, we created a transgenic 
hESC line using a Transposon-BAC system (see Materials and Methods), wherein 
GFP expression is under the control of the NANOG promoter. In order to validate that 
green fluorescence reflects the pluripotent state of NANOG-GFP hESCs, we 
transfected these cells with siRNAs against POU5F1 and GFP (Figure 10A-B). As 
expected, knockdown of POU5F1 has induced differentiation, as seen with the 
decrease in both green fluorescence and NANOG transcript levels. This demonstrates 
that the pluripotent state, NANOG expression levels, and the intensity of green 
fluorescence are all coupled together.  
Figure 9. Time-course expression profile of pluripotency markers upon the 
exit from pluripotency. Transcript levels were measured using microarray 
analysis. NANOG expression level experiences the most drastic decrease at both 
earlier and later time points. Error bars denote standard deviation of triplicate 
data. 





To confirm that the modified hESC line is suitable for downstream purposes, 
we performed cytogenetic analysis to find a normal karyotype with 46XY 
chromosomes (Figure 10C). Teratoma formation assay for NANOG-GFP hESCs also 
ensured that their pluripotency is uncompromised; NANOG-GFP hESC-derived 
teratomas comprised tissues from ectoderm, mesoderm and endoderm lineages 6 
Figure 10. Validations for the NANOG-GFP hESC line. (A) Images for 
NANOG-GFP fluorescence (green) and nuclei (blue) after transfection with 
siRNA controls. Scale bar = 300μm. (B) Expression level of NANOG as measured 
by qPCR after transfection with siRNA controls. Error bars denote standard 
deviation for triplicate data. (C) Cytogenetic analysis of NANOG-GFP cells 
confirms a normal karyotype of 46XY chromosomes. (D) NANOG-GFP hESCs 
gave rise to teratomas consisting of tissues from ectoderm, mesoderm and 
endoderm lineages. NANOG-GFP hESC line was generated with the help of Dr 
Gao Bin and Le Beilin. 
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weeks after injection into SCID mice (Figure 10D). Altogether, these results confirm 
that the hESC line generated is perfectly normal, and that GFP fluorescence levels in 
these cells accurately reflect their state of pluripotency. 
 
C. Optimization of differentiation conditions 
 To achieve robust and unbiased identification of universal and specific factors 
governing the exit from pluripotency, we performed the siRNA screen under multiple 
differentiation conditions. To dissect the signalling control of hESC maintenance, we 
wanted to individually perturb the bFGF and TGFβ pathways, in addition to the - 
bFGF, - TGFβ condition. Hence, we used the ALK5 kinase inhibitor A8301 to inhibit 
the TGFβ pathway (TGFβ pathway inhibition condition), and the MEK inhibitor 
PD0325901 to inhibit the bFGF-MEK axis (bFGF pathway inhibition condition). In 
addition, we included a fourth condition wherein we introduce a differentiation signal 
in the form of retinoic acid without withdrawing self-renewal signals (+ Retinoic acid 
condition). We ensured that all four conditions induce efficient exit from pluripotency 
by checking NANOG-GFP fluorescence (Figure 11A) and pluripotency marker 
expression at both the transcript (Figure 11B) and protein (Figure 11C) levels. 
Importantly, we observed a varied response in the upregulation of lineage-specific 
markers in the four conditions (Figure 11B), indicating that the different conditions 
we are using for the experiment lead to distinct differentiated fates. 
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Figure 11. Characterization of the four differentiation conditions. (A) Images 
for NANOG-GFP fluorescence (green) and nuclei (blue) after incubation in the 
respective conditions. Scale bar = 300um. (B) Expression levels of pluripotency 
and lineage-specific markers as measured by qPCR. Error bars denote standard 
deviation for triplicate data. (C) Images for immunofluorescence staining against 
pluripotency markers after incubation in the differentiation media. Scale bar = 
200μm. 
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D. Experimental design of the high-throughput RNAi screen 
 Assembly of all these primary results guided the final design of our high-
throughput RNAi screen (Figure 12). First, siRNA pools against genes of interest 
were introduced into the NANOG-GFP hESC line by reverse transfection in a 384-
well format. Given the large scale of the experiment, we limited our siRNA libraries 
to target a subset of the genome encompassing factors that can easily be targeted with 
small molecules (kinases, phosphatases and G-protein coupled receptors) and factors 
directly involved in gene expression regulation (chromatin modifiers and transcription 
factors). 24 hours after transfection, we initiate the exit from pluripotency by 
changing the culture medium to one of the four aforementioned conditions. After the 
differentiation period, hESCs are returned to the pluripotency medium to enrich for 
hESCs that have resisted the exit from pluripotency. The degree of preservation of 
hESC identity was subsequently measured through the average NANOG-GFP 
fluorescence intensity per cell, as hESCs depleted of genes crucial for the exit from 
pluripotency are expected to retain higher GFP signals. All in all, we screened a total 
of 4,558 genes in triplicate for all four conditions using pools of 3-4 independent 
siRNAs, summing up to 54,696 data points. 
 







Figure 12. Experimental design of the high-throughput RNAi screen. 
NANOG-GFP hESCs were transfected with siRNA pools in a high-throughput 
platform. Exit from pluripotency was induced using one of four differentiation 
conditions, and hESCs that resisted the exit from pluripotency were enriched by 
recovery in pluripotency medium. GFP fluorescence and cell number were finally 
measured from each well up to a total of 54,696 data points. 
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II. Quality control checks certify the robustness of the high-throughput RNAi screen 
 Before proceeding with the analysis of the screen results, it is imperative to 
check that the results obtained are of high quality. Quality control checks were put in 
place by assessing parameters such as plate alignment, plate layout effects, 
correlation, accuracy of fluorescence quantification, and cell number bias.  
 
A. Plate alignment 
High-throughput assays require samples to be distributed into experimental 
groups. In this large-scale RNAi screen, samples are divided into groups of up to 352, 
which is the maximum number that can be fitted into each culture plate. As 
environmental variations between plates are inevitable, plate-to-plate variation has to 
be accounted for to enable accurate analysis of screen results. We did this by aligning 
every plate with each other by calculating z-scores using the formula z = (X − µ)/s.d. 
where µ is the mean and s.d. is the standard deviation of of all samples within a plate 
(the full dataset of z-scores can be found in Supp. Tables 1-4). After z-score 
calculation, z-score distributions between each plate are perfectly aligned (Figure 13), 
negating any systematic bias that could have arisen between plates. 
 
 





B. Plate layout effects 
Ideally, all conditions within each group are kept identical. High-throughput 
assays are however vulnerable to plate layout effects, which arise due to irregularities 
in the conditions between the numerous samples in each plate (Maddox et al., 2008). 
Most common is the edge effect, wherein samples near the edges of the plate layout 
experience slightly different conditions (mainly variations in humidity levels) from 
Figure 13. Plate alignment of z-scores. Boxplots showing that data from each 
plate is properly aligned for the (A) - bFGF, - TGFβ, (B) TGFβ pathway 
inhibition, (C) bFGF pathway inhibition and (D) + Retinoic acid conditions after 
z-score normalization. Data shown are from the transcription factor and epigenetic 
modifier subsets of the library. 
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those around the centre of the plate. Heatmaps of normalized fluorescence values for 
representative plates from each of the four screening conditions show no observable 





C. Correlation between replicates 
We next checked for the correlation between replicates of each screening 
condition. There is a high linear correlation (R
2
>0.6) between all replicates of the 
TGFβ inhibition, bFGF inhibition and + Retinoic acid conditions, demonstrating 
Figure 14. Plate layout effects. Heatmaps of z-scores for representative plates 
from the transcription factor subset for the (A) - bFGF, - TGFβ, (B) TGFβ 
pathway inhibition, (C) bFGF pathway inhibition and (D) + Retinoic acid 
conditions. No visible plate layout biases were observed for all conditions. 
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excellent reproducibility (Figure 15A-C). The - bFGF, - TGFβ condition also showed 
good linear correlation (R
2
>0.4), albeit lower than the other three conditions (Figure 
15D). This can be attributed to the longer incubation time needed for exit from 
pluripotency to take place in - bFGF, - TGFβ, which provides more time for random 
variables to introduce noise into the results. Nevertheless, all conditions exhibit good 






Figure 15. Correlation between replicates. Scatter plots depicting linear 
correlation between two replicates from screens in the (A) TGFβ pathway 
inhibition, (B) bFGF pathway inhibition, (C) + Retinoic acid conditions and (D) - 
bFGF, - TGFβ are shown. Pearson correlation values (R2) for each combination of 
replicates are also indicated. 
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D. Accuracy of fluorescence quantification 
To certify that the z-scores accurately reflect GFP fluorescence, several 
samples from the wells with relatively high z-scores (z-score>1.25) were examined. 
We ascertained that all these samples have visibly higher fluorescence levels (Figure 






Figure 16. GFP fluorescence of wells with high z-scores. Representative images 
for NANOG-GFP fluorescence (green) and Hoescht staining (blue) for hits in the 
four differentiation conditions are shown. All samples show visibly higher GFP 
signals compared to the siNT negative controls. Scale bar = 300μm. 
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E. Cell number bias 
Furthermore, correlations between the z-scores and cell viability scores were 
calculated to detect if there is any cell number bias. All four conditions demonstrate 
that there is no substantial correlation (R
2
<0.1) between cell number and GFP 
fluorescence (Figure 17). Therefore, potential hits and non-hits from the screen both 
 
Figure 17. Cell number bias. Scatter plots depicting linear correlation between 
the mean z-scores and the mean cell viability scores from screens in the (A) - 
bFGF, - TGFβ, (B) TGFβ pathway inhibition, (C) bFGF pathway inhibition and 
(D) + Retinoic acid conditions are shown. Pearson correlation values (R
2
) for each 
combination of replicates are also indicated. All conditions show very poor 
correlation, indicating the absence of cell number bias in all of the conditions. 
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span a wide range of cell numbers, eliminating the possibility that housekeeping 
genes would be wrongfully detected as false positives or false negatives. 
 
F. Counter-screening using an ACTIN-GFP reporter 
Finally, counter-screens using a hESC line harbouring an ACTIN-GFP 
reporter were conducted on a subset of the conditions. Samples that consistently give 
out a higher GFP signal versus the negative control (z-score > 1.25 in at least 2 
replicates) were tallied, and no overlap between the list of genes for the NANOG-GFP 
and ACTIN-GFP reporters were found (Figure 18). This is conceivable as ACTIN-
GFP should not decrease with the exit from pluripotency. Hence, the only hits that 
could be detected are those that those directly upregulate ACTIN expression, which 








Figure 18. Overlap with ACTIN-GFP hESC counter-screens. Venn diagrams 
showing overlap of samples with z > 1.25 for at least 2 replicates in the ACTIN-
GFP screens and NANOG-GFP screens for the kinase, phosphatase and GPCR 
subsets of the library. No overlap is observed. 
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G. Hit selection from the high-throughput RNAi screen results 
 The goal of this high-throughput assay is to identify genes that are critical for 
the exit from pluripotency of hESCs. Filtering these from the rest of the samples 
requires a sensible cut-off. With this in mind, samples that reproducibly gave a z-
score > 1.25 or 1.5 in at least 2 replicates were considered as hits. These cut-offs are 
stringently above noise levels (Figure 19) while allowing a reasonable number of 




Figure 19. Z-score cut-off for hit selection. Descending plots of mean z-scores 
of screens in the (A) - bFGF, - TGFβ, (B) TGFβ pathway inhibition, (C) bFGF 
pathway inhibition and (D) + Retinoic acid conditions are shown. Blue horizontal 
line demarcates the selected cut-off, which are all above noise levels (as measured 
using untreated wells and the inflection point).  
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for TGFβ pathway inhibition, 138 hits for the bFGF pathway inhibition and 325 hits 
for + Retinoic acid. The full list of hits for each condition can be viewed in 
Appendices 3-6. 
To validate the hits filtered out by this experiment, we selected a panel of 
genes and designed 2 independent RNAi constructs for each gene (Figure 20A). This 
includes many cell cycle-associated genes (Figure 20B), which we will focus on later 
in this thesis. We considered hits to be true positives if both constructs prevented the 
decrease of majority of the pluripotency markers tested upon exit from pluripotency. 
Altogether, we managed to validate 80.6% of the hits across the first three conditions 
(Figure 20B-F), confirming that these hits are true positives.  
 
Altogether, these quality control checks establish that the screen is able to rigorously 
identify genes important for the exit from pluripotency of hESCs.  
 











Figure 20. Independent validations of hits.  (A) Transcript levels of respective 
genes upon RNAi knockdown as measured by qPCR. All RNAi constructs 
effectively decreased expression of their target gene. (B-E) Expression levels of 
pluripotency markers upon knockdown of hits in the (B,C) - bFGF, - TGFβ, (D) 
TGFβ pathway inhibition and (E) bFGF pathway inhibition conditions as 
measured by qPCR. Red crosses indicate false positives. All error bars denote 
standard deviations of triplicate data. (F) Pie chart depicting the percentage of hits 
validated. qPCR experiments were done with the help of Yee Siang Lim. 
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III. Independent analyses of screen results from each condition identify context-
specific mechanisms regulating the exit from pluripotency 
 We first ventured to independently analyse the results from each screening 
condition by looking for processes, pathways and associations enriched within the list 
of hits from each screening condition. We employed protein interaction analysis using 
STRING and HPRD (Figure 21), pathway enrichment analysis using Reactome 
(Figure 22) and gene ontology analysis using DAVID (Figure 23) (see Materials and 
Methods). These platforms revealed the prevalence of context-dependent processes 
that are critical for the exit from pluripotency.  
 
A. Procurement of hits expected in each screening condition 
 We expect that the list of hits should include factors that are associated with 
the primary pathways transducing the distinct initial differentiation cues in each 
condition. This is because perturbation of these primary pathways can nullify the 
differentiation-inducing effect stemming from the same pathway. Indeed, we find 
repressors of TGFβ-responsive genes (such as SKI and SKIL) to be enriched when 
upstream TGFβ signalling is inactive (Figure 21, 22B). It was reassuring to find 
similar results in other conditions, wherein the retinoic acid receptor and inactivators 
of ERK (DUSP4, DUSP6) are enriched in the hits for the + Retinoic acid and bFGF 
pathway inhibition conditions, respectively (Appendices 5,6).  
Furthermore, we observe that retinoic acid-mediated exit from pluripotency 
relies heavily on transcription as members of the RNA polymerase II and 
TFIID/Mediator complexes are enriched in the hits (Figure 21, 22D, 23D). This is 
anticipated as the retinoic acid receptor is a transcription factor, requiring high 
activity of the general transcriptional machinery to elicit its effects on the exit from 
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pluripotency (Lefebvre et al., 2005). Altogether, these results demonstrate the 






Figure 21. Protein interaction networks of hits. Protein-protein interaction 
networks of genes that are uniquely enriched for the different screening 
conditions. Node color indicates the screening conditions wherein the gene was 
identified as a hit. 
 




B. The NuRD complex in the exit from pluripotency 
 More interestingly, some processes seem to be more important in the exit from 
pluripotency given specific differentiation triggers. For example, members of the 
NuRD were identified as hits for regulating the exit from pluripotency particularly 
during bFGF-MEK inhibition (Figure 21, 23C). The NuRD complex, especially its 
fundamental member Mbd3, has an established role in promoting PSD in mESCs 
(Kaji et al., 2006; Reynolds et al., 2012), and our results demonstrate the conservation 
 
 
Figure 22. Reactome analysis. Top pathways that are overrepresented (p<0.05) 
among the hits as determined using the web resource Reactome in the (A) - bFGF, 
- TGFβ, (B) TGFβ pathway inhibition, (C) bFGF pathway inhibition and (D) + 
Retinoic acid conditions conditions are shown. 
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of this function in hESCs. Interestingly, while the LIF-Stat3 pathway opposes the 
action of the NuRD complex in mESCs (Hu and Wade, 2012), this role seems to be 
assumed by the bFGF-MEK pathway in hESCs. 
In seeming contrast to our results, there are also specific NuRD complex 
members that function to promote the pluripotent state instead (Liang et al., 2008). 
These discrepancies potentially arise from the presence of multiple NuRD complex 
isoforms that play opposite functions in ESCs. Our screen provides a starting point to 
classify the function of different NuRD members, with our hits specifically being the 




Figure 23. Gene ontology analysis. Top gene ontology functional clusters that 
are overrepresented (p<0.05) among the hits as determined using the web resource 
DAVID in the (A) - bFGF, - TGFβ, (B) TGFβ pathway inhibition, (C) bFGF 
pathway inhibition and (D) + Retinoic acid conditions conditions are shown. 
 
  54 
 
C. Context-dependent function of development-related signalling pathways 
 Wnt-associated factors, particularly those involved with β-catenin, were also 
enriched in the bFGF pathway inhibition condition (Figure 21, 22C, 23C), indicating 
that the exit from pluripotency upon bFGF-MEK inhibition crosstalks with the 
canonical Wnt signalling pathway. While the role of Wnt signalling in hESC 
pluripotency has been controversial, most reports now agree that Wnt-β-catenin signaling 
works towards differentiation (Cai et al., 2007; Davidson et al., 2012; Dravid et al., 2005; 
Sumi et al., 2008; Ullmann et al., 2008). Our results support this current consensus, as the 
knockdown of canonical Wnt pathway members was able to promote the pluripotent 
state. The specificity of this observation to the context of inactive bFGF-MEK 
signalling is intriguing, as it suggests the existence of an additional layer of crosstalk 
between the two involved pathways. It is known that ERK reinforces the canonical 
Wnt pathway by phosphorylating and consequently inhibiting GSK3 (Ding et al., 
2005; Singh et al., 2012). Disruption of ERK and canonical Wnt signalling might 
have a synergistic effect that converges on β-catenin regulation and perhaps other 
downstream connecting nodes.  
Another notable pathway that highlights the divergent roles that pathways can 
play in different contexts is the PI3K pathway. The PI3K pathway is known to 
support pluripotency in hESCs by coordinating with both bFGF and TGFβ pathways 
(Li et al., 2007; Singh et al., 2012). Accordingly, we find negative regulators of this 
pathway to be enriched in the - bFGF, - TGFβ condition (Figure 22A). Yet, in the 
context of RA-induced exit from pluripotency, the PI3K seems to switch function to 
one antagonizing the pluripotent state (Figure 21, 22D), like its role downstream of 
RA in promoting differentiation in other cell types (Bastien et al., 2006; Qiao et al., 
2012). This observation can be independently validated with LY294002, a small 
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molecule inhibitor of PI3K. Supplementation of LY294002 accelerated the decrease 
in pluripotency markers in the pluripotency medium and - bFGF, - TGFβ conditions, 






Figure 24. Validation of context-dependent roles of the PI3K pathway with 
small molecules. (A) Representative images for NANOG-GFP fluorescence 
(green) and nuclear staining (blue) after treatment with small molecules. Scale bar 
= 500μm. (B) Expression levels of pluripotency markers upon treatment with 
LY294002 (PI3K inhibitor) as measured by qPCR. All error bars denote standard 
deviation of triplicate data. 
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These results emphasize the importance of studying the role of developmental 
pathways in the proper context, as it is commonplace for these pathways to play 
opposite functions depending on environmental cues and crosstalk with other 
pathways (Kim et al., 2013; Singh et al., 2012). 
 
D. The role of splicing in the exit from pluripotency  
Interestingly, the RNA splicing machinery also seems to play a role in the exit 
from pluripotency, especially during retinoic acid addition and bFGF-MEK inhibition 
(Figure 22C-D, 23C-D). This is notable because although multiple RNA splicing 
factors have been reported to control hESC pluripotency (Gabut et al., 2011; Lu et al., 
2013; Lu et al., 2014), it was unknown hitherto whether they also regulate its exit. 
RNA splicing has been shown in other species to play a major role in 
regulating the Ras-MAPK-ERK cascade (Ashton-Beaucage et al., 2014; Shilo et al., 
2014), which is pivotal to the role of bFGF in maintaining the human pluripotent state 
(Li et al., 2007; Xu et al., 2005). Similarly, retinoic acid has been reported to 
influence RNA splicing in human embryonic kidney cells through its interaction with 
Acinus (Wang et al., 2014). Similar mechanisms might be in place in hESCs, 
explaining why RNA splicing could affect the exit from pluripotency triggered 
specifically by bFGF pathway inhibition or retinoic acid introduction. Our study 
therefore opens the door for studying the crosstalk between the splicing machinery, 
the exit from pluripotency, and these developmental pathways. 
 
In conclusion, independent analyses of the various screening conditions identify 
context-dependent processes that are crucial for the exit from pluripotency, in addition 
to demonstrating the robustness of our screen results.  
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IV. Combined analysis of screen results reveals universal pathways governing the exit 
from pluripotency upon the withdrawal of self-renewal signals 
 
A. Hierarchical clustering of the four screening conditions 
To get a general overview of the relationship between the four conditions, we 
performed hierarchical clustering analysis of the overall results from the four 
conditions. Each condition clustered within its own replicates, but away from other 
conditions (Figure 25). This reinforces the presence of diverse responses during the 
exit from pluripotency of hESCs given distinct differentiation triggers, which we have 
discussed in the previous section.  
Interestingly, the - bFGF, - TGFβ, TGFβ pathway inhibition and bFGF 
pathway inhibition conditions weakly cluster together, but not with the + Retinoic 
acid condition (Figure 25). This was conceivable given that the + Retinoic acid 
condition introduces a differentiation signal in contrast to the withdrawal or inhibition 
of self-renewal signals in the other 3 conditions. This implies that the effectors of 
PSD vary when self-renewal signals are withdrawn versus when a differentiation 
signal is introduced, and that the mode of differentiation induction greatly influences 
PSD regulation. 
Given the similarity between the aforementioned clustering conditions, we 
next performed a combined analysis of these three conditions to find central pathways 
that are important for the exit from pluripotency in the absence of self-renewal signals 
(Figure 26). The significance of epigenetic modification and the cell cycle in the exit 
from pluripotency is highlighted in this combined analysis, with members of multiple 
chromatin modifying complexes and cell cycle pathways being enriched.  
 




B. Histone acetylation and the exit from pluripotency 
Differentiation is often accompanied by changes in histone acetylation (Golob 
et al., 2008; Legartova et al., 2014), and accordingly, histone acetyltransferase (HAT) 
complex proteins appear to be top hits (Figure 26A-C), most prominently those that 
belong to SAGA-type and NuA4 (also known as Tip60-p400) HAT complexes. 
Markedly, the catalytic subunit of the NuA4 complex KAT5 is among the top 5 hits of 
all three conditions (Appendices 3-5).  
The NuA4 HAT complex has been previously implicated in the regulation of 
pluripotency, wherein its downregulation compromises the ability of mESCs to 
robustly give rise to differentiated cells (Chen et al., 2013; Fazzio et al., 2008). This 
feature of the NuA4 HAT complex seems to be conserved in hESCs. In contrast, the  
Figure 25. Hierarchical clustering of screening conditions. Heatmap depicting 
hierarchical clustering by Euclidean distance between different screening 
conditions. - bFGF, - TGFβ, TGFβ pathway inhibition and bFGF pathway 
inhibition results weakly cluster together and away from + Retinoic acid results. 





Figure 26. Combined analysis of conditions wherein self-renewal signalling is 
withdrawn. (A) Enriched gene clusters from the protein-protein interaction 
network analysis of the combined hits. Node size indicates the average z-score of 
the hits, while node color indicates the degree of integration (number of edges) of 
the gene with the entire network of hits. (B) Reactome analysis. Overrepresented 
pathways (p<0.05) from the combined hits as determined using the web resource 
Reactome are shown. (C) Gene ontology analysis. Representative terms (p<0.05) 
for enriched functional clusters from the combined hits are shown. 
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effect of SAGA-type HAT complexes on the exit from pluripotency seems to be 
unique for hESCs. While there is little literature on this topic, a study has 
demonstrated that knockout of the major SAGA catalytic subunit Gcn5 (or KAT2A in 
humans) in mESCs diminished their viability but not their differentiation capacity 
(Lin et al., 2007). In fact, the Gcn5-null mESCs even exhibited accelerated 
downregulation of a few pluripotency markers. Therefore, in contrast to the conserved 
function of the NuA4 HAT complex, species-specific differences might exist for the 
role of SAGA-type complexes in the exit from pluripotency. Interestingly, it has also 
been reported that Gcn5 depletion provokes cell cycle arrest at the G2/M checkpoint 
upon induction of differentiation (Lin et al., 2007), in line with our findings on the 
regulation of the exit from pluripotency by the cell cycle, which will be discussed 
later in this thesis. 
Histone acetylation levels are higher in ESCs compared to somatic cells 
(Meshorer et al., 2006); we would therefore expect that differentiation is accompanied 
by histone deacetylation. Contrary to this expectation, two major HAT complexes 
were universally implicated in the exit from pluripotency upon withdrawal of self-
renewal signals, while HDACs were not highly enriched in the combined screen hits. 
It thus seems that during the initiation of the exit from pluripotency, histone 
acetylation rather than deacetylation is required.  
This could be attributed to the global but transient upsurge in histone 
acetylation that occurs at the onset of the exit from pluripotency (Golob et al., 2008; 
McCool et al., 2007). We hypothesize that this global increase in histone acetylation 
levels is an essential part of the exit from pluripotency that occurs specifically at 
differentiation gene loci. This enables ESCs to expansively acquire expression of 
genes from across multiple lineages, thus conferring pluripotency. Blockade of this 
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histone acetylation wave could thus inhibit exit from pluripotency due to the failure to 
upregulate differentiation-associated gene expression. Alternatively, these complexes 
might target specific loci, likely other effectors of the exit from pluripotency, 
necessitating their activity to complete the process of the exit from pluripotency. 
While these complexes target a broad range of histone marks and loci, there is a 
definite degree of specificity by these complexes that make them uniquely important 
for the exit from pluripotency, as other histone acetylation complexes such as HBO1 
and PCAF complexes were not detected as hits in the screen. However, there is no 
study to date that has identified the loci targeted by either of these complexes in 
hESCs; this will be the next important step to understand how these HAT complexes 
regulate the exit from pluripotency by determining the identity of the genes they 
regulate. 
 
C. The SWI/SNF nucleosome remodelling complex in the exit from pluripotency 
Another chromatin modifying complex implicated in our study is the 
SWI/SNF nucleosome remodelling complex (Figure 26A,C). Multiple members of the 
SWI/SNF complex that were detected as hits in our screen have been demonstrated to 
function in the differentiation of multiple cell types (de la Serna et al., 2006). 
Specifically, the SWI/SNF factor BRG1 (encoded by SMARCA4) has been reported to 
antagonize Myc activity in cancer cells (Romero et al., 2012). The SWI/SNF complex 
might promote the exit from pluripotency by shutting down the Myc module, since 
Myc is well-known to be important for self-renewal of ESCs (Smith et al., 2010; 
Varlakhanova et al., 2010). However, there also exists seemingly contrasting 
evidence, where the SWI/SNF complex was regarded to be important for pluripotency 
maintenance, not exit (Zhang et al., 2014). Specifically, they report that BRG1 
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negatively modulates H3K27ac levels in multiple lineage-specific gene loci, thus 
contributing to pluripotency maintenance. However, the same study also showed that 
a unique SWI/SNF composition containing BAF170 (encoded by SMARCC2) but 
excluding BAF155 (encoded by SMARCC1) was responsible for this effect (Zhang et 
al., 2014). Interestingly, our screen identified SMARCC1 but not SMARCC2 to be 
enriched in the hit list. This means that different compositions of the same complex 
perform divergent functions in hESCs, and the screen results enable us to sift out 
which members of the SWI/SNF complex are specifically important for the exit from 
pluripotency in hESCs. 
 
Notably, the role of these various complexes in the exit from pluripotency seems to be 
highly conserved, as inhibition of these complexes have been shown to impair 
differentiation in mouse embryonic stem cells (mESCs) (Chen et al., 2013; Lin et al., 
2007) and cancer cells (Romero and Sanchez-Cespedes, 2013). Certain members of 
these complexes, such as Trrap of the NuA4 HAT complex and Arid1a of the 
SWI/SNF complex, have also been found to be crucial for exit from pluripotency of 
mESCs (Betschinger et al., 2013). Thus, our study systematically identified several 
chromatin-modifying complexes to be universally important for the exit from hESC 
pluripotency upon withdrawal of self-renewal signals. 
 
D. The cell cycle in the exit from pluripotency 
Genes involved in cell cycle regulation are among the most enriched in 
conditions where self-renewal signals were withdrawn (Figure 26A-C). Strikingly, the 
cell cycle-associated hits are mostly involved in the G2-to-M transition or in DNA 
replication during the S phase (Figure 26A). On the contrary, we found no strong 
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enrichment of processes specific to the G0/G1 phase and mitotic progression. This 
suggests that the exit from pluripotency is gated by specific mechanisms hardwired to 
cell cycle progression. We therefore decided to focus on examining how the exit from 
pluripotency is regulated by the cell cycle machinery, which will be discussed in 
detail later in this thesis. 
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V. Combined analysis of screen results additionally identify genes that enhance the 
exit from pluripotency 
 While the focus of this project is to look for genes that are important for the 
exit from pluripotency, the high-throughput RNAi screen also enabled the 
identification of genes that function in the opposite direction. Hence, we likewise 
performed a combined analysis of genes whose knockdown enhanced the exit from 
pluripotency (negative z-scores) in the three clustering conditions (Figure 27).   
 
A. Known guardians of the pluripotent state  
 As expected, direct knockdown of members of the core pluripotency network 
itself accelerated the exit from pluripotency (Figure 27A-B). This analysis also 
encouragingly sieved out positive regulators of the chief pathways of the maintenance 
of hESC pluripotency, namely the TGFβ and bFGF signalling pathways (Figure 27A-
C). This is in parallel to the enrichment of negative regulators of these same pathways 
in the hits that prevent the exit from pluripotency. Hence, we see that genes with 
opposite functions yielded opposite scores in the RNAi screen, underlining the 
robustness of the RNAi screen results. 
 
B. Chromatin modification in the maintenance of pluripotency 
 It is well-known that cell fate maintenance and transitions are highly 
dependent on the epigenetic state of the cell. This is strikingly exemplified by the 
importance of chromatin modifying complexes in promoting the exit from 
pluripotency as discussed in the previous section. Likewise, a different set of 
chromatin modifiers are essential for upholding the pluripotent state.  
 





Figure 27. Combined analysis of hits that enhance the exit from pluripotency 
(negative z-scores). (A) Enriched gene clusters from the protein-protein 
interaction network analysis of the combined hits. Node size indicates the average 
z-score of the hits, while node color indicates the degree of integration (number of 
edges) of the gene with the entire network of hits. (B) Reactome analysis. 
Overrepresented pathways (p<0.05) from the combined hits as determined using 
the web resource Reactome are shown. (C) Gene ontology analysis. 
Representative terms (p<0.05) for enriched functional clusters from the combined 
hits are shown. 
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Particularly, members of histone deacetylase (HDAC) complexes were 
enriched in the hits (Figure 27A). Whilst the knockdown of HATs attenuated the exit 
from pluripotency as discussed earlier, knockdown of HDACs accelerated the exit 
from pluripotency. This reiterates that histone acetylation is a central process 
necessary for the exit from pluripotency to manifest. 
 A distinct epigenetic feature of the pluripotent state is the presence of bivalent 
domains, characterized by the presence of both the repressive histone 3 lysine 27 
trimethylation mark (H3K27me3) and the activating histone 3 lysine 4 trimethylation 
mark (H3K4me3) (Azuara et al., 2006; Bernstein et al., 2002; Pan et al., 2007; Zhao 
et al., 2007). Bivalent domains are hence believed to mark developmental genes in a 
poised state, which are primed for rapid and immediate induction upon differentiation 
(Sha and Boyer, 2008). These modifications are deposited by the Polycomb repressive 
complex 2 (PRC2) and the Trithorax complex, respectively. Although both complexes 
are conceivably crucial for the integrity of the pluripotent state, only the PRC2 
complex has been extensively studied to be essential for the maintenance of 
pluripotency (Boyer et al., 2006; Lee et al., 2006). Nevertheless, the Trithorax core 
member Ash2l has recently been implicated in the maintenance of mESCs (Wan et 
al., 2013). Our screen results highlight the role of the Trithorax complex in 
specifically in promoting hESC pluripotency, as knockdown of multiple Trithorax 
group proteins all resulted in the accelerated exit from pluripotency (Figure 27A). 
 
In conclusion, our high-throughput RNAi screen has enabled the identification of both 
positive and negative regulators of the exit from pluripotency. The results from this 
study will henceforth serve as a unique resource for the stem cell field to explore in 
detail the mechanisms underlying the exit from pluripotency.  
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VI. The cell cycle exerts profound control over the exit from pluripotency 
We have found that many genes involved in cell cycle regulation affect the 
exit from pluripotency, specifically those functioning during the S and G2 phases of 
the cell cycle (Figure 26A-C). Specifically, we have found 14 genes that are involved 
in DNA replication, and 14 genes involved in the G2/M transition.  
During proliferation, cells experience dramatic biochemical and physical 
changes, which cells have evolved to utilize in order to prime and regulate other 
events that are not immediately related to proliferation. Biochemical differences 
within various cell cycle states were shown to extend their function to regulate 
immune response, metabolism and lineage specification (Handschick et al., 2014; Lee 
et al., 2014; Pauklin and Vallier, 2013; Rodier et al., 2009). Despite increasing 
evidence showing the cell cycle regulating other cellular process, there is no direct 
and functional evidence that cell cycle states can control the pluripotency network and 
its dissolution. As the screen results seem to suggest that the core cell cycle 
machinery may enforce a deterministic regulation on pluripotency and differentiation 
in hESCs, we focused on examining how the exit from pluripotency is regulated by 
the cell cycle machinery. 
 
A. Validation of S- and G2-associated hits 
 We first sought to validate the prevention of the exit from pluripotency by 
knockdown of S- and G2-associated hits. In the - bFGF, -TGFβ condition, knockdown 
of all hits examined can remarkably be validated with 2 independent shRNAs (Figure 
20B). Knockdown of majority of these genes similarly caused retention of NANOG-
GFP fluorescence in the TGFβ pathway inhibition and bFGF pathway inhibition 
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conditions (Figure 28). Therefore, we are confident that these S- and G2-associated 
genes truly play a role in the exit from pluripotency. 
 
 
B. Perturbation of cell cycle progression by knockdown of hits 
We next checked if their knockdown affects cell cycle progression in hESCs. 
Knockdown of the S-associated hits led to the elevation of γH2AX foci (Figure 29), 
which results from the activation of the replication checkpoint upon perturbation of 
DNA replication. This can be mimicked by treatment of hESCs with the DNA 
polymerase inhibitor Aphidicolin (Figure 29), which is proven to block DNA 
replication during the S phase (Pedrali-Noy et al., 1980). On the other hand, 
knockdown of G2-associated hits increased the relative time spent by hESCs in the 
 
 
Figure 28. Cell cycle-associated hit knockdown in conditions wherein self-
renewal signalling is withdrawn.  Representative images for NANOG-GFP 
fluorescence (green) and nuclear staining (blue) after RNAi knockdown of select 
cell cycle-associated hits. Scale bar = 500μm. 
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G2 phase (Figure 30). Thus, we confirm that knockdown of the S- and G2-associated 
hits impedes progression at the S and G2 phases, respectively. 
 
 





Figure 29. Presence of γH2A.X foci upon knockdown of S-associated hits.  
Representative images of nuclei (blue) and anti-γ-histone 2A.X 
immunofluorescence staining (red) of hESCs after RNAi knockdown of 
replication-associated hits or treatment with Aphidicolin in the pluripotency 
medium. Scale bar = 10μm. Staining was done with the help of Dr Liang 
Hongqing. 









Figure 30. Cell cycle profile of hESCs upon knockdown of G2-associated hits.  
(A) FACS profiles and (B) Flow cytometry quantification indicating the cell cycle 
status of hESCs after RNAi knockdown of G2-associated hits in the pluripotency 
medium.  
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C. Perturbation of cell cycle progression by small molecules 
To validate that resistance to the exit from pluripotency can indeed be 
conferred by specific cell cycle changes, we employed a collection of chemical 
inhibitors known to perturb various cell cycle pathways. With extensive dosage 
titration, we managed to enrich but not completely arrest hESCs in the various cell 




Figure 31. Cell cycle profile of hESCs upon treatment with cell cycle 
inhibitors.  Flow cytometry quantification indicating the percentage of hESCs in 
the (A) G1, (B) S, (C) G2 and (D) M phases of the cell cycle after treatment with 
various chemicals known to perturb the cell cycle in the pluripotency medium.  
  72 
 
our screen results, chemicals that perturb DNA replication in the S phase (5-
hydroxyurea, Aphidicolin) or delay progression through the G2 phase by inhibiting 
mitotic entry (RO3306, Alisertib, Nocodazole) can significantly preserve the 
expression of pluripotency markers (Figure 32A-B) and NANOG-GFP fluorescence 
(Figure 32C) when self-renewal signals were withdrawn. In contrast, inhibitors that 
led to enrichment in other cell cycle phases did not exhibit such an effect (Figure 30). 
Importantly, these observations are not exclusive to the hESC line used, as the same 
trend is also observed in other hESC lines (Figure 32D).  
 
Therefore, we provide evidence through both genetic and chemical means that hESCs 
inevitably preserve their pluripotent state despite withdrawal of self-renewal signals 
when their progression through the S and G2 phases is hindered (Figure 33). In 
contrast, the exit from pluripotency ensues despite perturbations in the G1 and M 
phase (Figure 33). These suggest that the exit from pluripotency is strongly governed 
by specific factors or pathways within the cell cycle machinery.  
Some studies have previously shown that hESCs in the G1 phase are more 
sensitive to the initiation of differentiation compared to S and G2 phase cells (Pauklin 
and Vallier, 2013; Sela et al., 2012). Yet, this is the first demonstration that 
perturbation of the cell cycle at the S and G2 phases is sufficient to attenuate the exit 
from pluripotency in hESCs, providing proof-of-concept that manipulation of the hES 
cell cycle can deterministically influence its cell fate decisions.  
Moreover, cells in the M phase were excluded or pooled into the other phases 
in the previous studies, but we show here that perturbation at the M phase does not 
prevent exit from pluripotency. Multiple characteristics of the M phase prevent it 
from enforcing cell fate transitions: its very short duration compared to other cell 
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cycle phases (Becker et al., 2006; Gordon and Lane, 1980), the lack of transcriptional 
activity throughout the phase (Gottesfeld and Forbes, 1997; Martinez-Balbas et al., 
1995; Prescott and Bender, 1962), and its inherent intolerance to perturbations. Thus, 
it is unlikely that there are mechanisms that take place for promotion of either 
pluripotency or differentiation in the M phase. Instead, the observations for cells in 
the M phase are probably an extension from the following G1 phase. Mitotic arrest 
results in transcriptional inhibition and DNA damage, that ends up either in apoptosis 
or mitotic slippage into a senescent G1 phase (Blagosklonny, 2007; Lanni and Jacks, 
1998). As our experiments for the M phase only involved chemical perturbations, 
most of the surviving cells are probably the ones which have slipped into the G1 

















Figure 32. Effects of various cell cycle inhibitors on the exit from 
pluripotency.  (A-C) Expression levels of pluripotency markers upon treatment 
with cell cycle inhibitors in the - bFGF, - TGFβ condition as measured by (A) 
qPCR, (B) immunofluorescence staining (Scale bar = 200um) and (C) NANOG-
GFP fluorescence (Scale bar = 500μm). (D) Expression levels of pluripotency 
markers upon treatment of additional hESC lines with cell cycle inhibitors in the - 
bFGF, - TGFβ condition as measured by qPCR. All error bars denote standard 
deviation of triplicate data. 
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Figure 33. Model for cell cycle dependency of the exit from pluripotency. 
hESCs are amenable to the exit from pluripotency during the G1 and M phases, 
while they tend to preserve their identity and prevent the exit from pluripotency 
during the S and G2 phases. 
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VII. G1-specific factors do not deterministically regulate the exit from pluripotency 
Embryonic stem cells spend the majority of their time in the S and G2 phases 
of the cell cycle, in contrast to differentiated cells which spend more time in the G1 
phase (Coronado et al., 2013; Hindley and Philpott, 2013; Singh and Dalton, 2009). 
The current paradigm is that G1 is the only phase permissive to differentiation, 
attributed to a higher expression of differentiation markers (Singh et al., 2013) and the 
enrichment of cell cycle factors like CDK inhibitors and Cyclin D that contribute to 
lineage specification (Li et al., 2012a; Pauklin and Vallier, 2013). In the other phases 
of the cell cycle, hESCs are believed to be passively retained in the pluripotent state 
due to the “lack” of a differentiation response pathway. Hence, one could argue that 
prolongation of the S and G2 phases is simply a result of blocked access to the G1 
phase.  
 
A. Expression levels of G1-associated factors upon perturbation of S and G2 phases   
To test if the delayed exit from pluripotency resulting from cell cycle 
perturbation at the S and G2 phases was due to an inaccessibility to G1-associated 
factors, we firstly examined the expression levels of major G1-specific factors that are 
implicated in differentiation (Li et al., 2012a; Pauklin and Vallier, 2013). Neither 
Cyclin D1 nor p21 protein was downregulated upon knockdown of S and G2 phase-
related hits (Figure 34), indicating that the consequent prevention of the exit from 
pluripotency is not due to an inaccessibility to these G1-associated factors.  
 
B. Knockdown of G1-specific factors 
We next knocked down factors required for G1 phase progression such as 
Cyclin D1/2 or CDK4/6. If these factors mediate the exit from pluripotency, their 
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depletion is expected to attenuate the exit from pluripotency. If other G1-specific 
factors are instead required, their depletion should enhance the exit from pluripotency 
due to the resulting elongation of the G1 phase. However, neither of these were 
observed as knockdown of any of these factors had no consistent effect on 
pluripotency gene expression (Figure 35), suggesting that G1-associated factors do 
not deterministically govern the shutdown of the pluripotency network. 








Figure 34. Expression levels of G1-specific factors upon S and G2 phase 
perturbation. Western blot of (A) Cyclin D1 and (B) p21 levels upon knockdown 
of S- and G2-associated hits. No downregulation of either protein was observed. 





C. Overexpression of G1-specific factors 
To finalize that G1-specific factors do not directly regulate the exit from 
pluripotency, we examined whether the shutdown of pluripotency marker expression 
can be enhanced by ectopic overexpression of certain G1-specific factors that are 
implicated in differentiation. Direct overexpression of either Cyclin D1 or p21 did not 
significantly affect the exit from pluripotency (Figure 36), in line with the prior 
observations. 
Figure 35. Effect of G1-associated factor knockdown on the exit from 
pluripotency. (A) Transcript levels of respective genes upon RNAi knockdown 
as measured by qPCR. All RNAi constructs effectively decreased expression of 
their target gene. (B) Expression levels of pluripotency markers upon knockdown 
of G1-associated genes in the - bFGF, - TGFβ condition as measured by qPCR. 
All error bars denote standard deviation of triplicate data. Experiments were done 
with the help of Dr Liang Hongqing. 
 




Altogether, these suggest that although G1-associated factors were reported to 
contribute to lineage specification, they are not determinants in shutting down the 
pluripotency network in this context. These findings in hESCs highly resemble 
previous findings in mESCs, in which a longer G1 phase is coupled to differentiation 
but targeting of G1-specific factors does not affect the exit from pluripotency (Li et 
al., 2012c). Therefore, the attenuation of the exit from pluripotency by S and G2 
phase perturbation cannot be completely explained to be driven by G1-specific 
factors, breaking the G1-centric paradigm of pluripotency control by the cell cycle. Instead, 
we hypothesize that pathways which are independent of G1 but are overstimulated by 
either DNA replication error or G2 phase perturbation may play a more deterministic 





Figure 36. Effect of G1-associated factor overexpression on the exit from 
pluripotency. (A) Protein levels of respective genes upon overexpression as 
measured by Western blot. Both overexpression constructs effectively increased 
expression of their target gene. (B) Expression levels of pluripotency markers 
upon overexpression of G1-associated genes in the - bFGF, - TGFβ condition as 
measured by qPCR. All error bars denote standard deviation of triplicate data. 
Experiments were done with the help of Dr Liang Hongqing. 
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VIII. Activation of the DNA replication checkpoint in the S phase attenuates the exit 
from pluripotency 
 To test the hypothesis that the cell cycle-dependent regulation of the exit from 
pluripotency might stem from a direct effect of S- and G2-specific pathways, we 
looked for specific cell cycle machineries that could crosstalk with the pluripotency 
network. One major outcome of DNA replication perturbation during the S phase is 
the activation of the DNA replication checkpoint (Bakkenist and Kastan, 2003; Zou 
and Elledge, 2003), which halts the cell cycle until the replication fork stalling and the 
consequent DNA damage are resolved (Recolin et al., 2014). In brief, replication 
checkpoint signalling is mainly mediated by the sensor kinases ATM and ATR, which 




Figure 37. The DNA replication checkpoint pathway. Activation of the DNA 
replication checkpoint activates the sensor kinases ATM and ATR, which in turn, 
activates CHEK1 and CHEK2 directly or through several mediators. The CHEKs 
activate a multitude of effectors to regulate various processes including 
transcription, cell cycle progression and DNA repair. Adapted from Elledge Lab 
2014 (http://elledgelab.med.harvard.edu) with permission from Dr. Steve Elledge. 
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both ATM/ATR and the CHEKs are then activated, coordinating processes such as 
DNA repair, cell cycle progression, apoptosis and gene expression to rectify errors 
before resumption of DNA replication. 
 
A. Activation of the DNA replication checkpoint 
To ensure that the DNA replication checkpoint is activated in our experiments, 
we looked at phosphorylation levels of the effector kinases CHEK1 and CHEK2 upon 
exposure to DNA polymerase inhibitor Aphidicolin. Aphidicolin treatment increased 
levels of both pCHEK1 and pCHEK2 (Figure 38). Treatment with the pan-CHEK 
inhibitor AZD7762 further enhanced phosphorylation CHEK1 and CHEK2 (Figure 
36), resulting from negative feedback. Furthermore, activation of the checkpoint is 
substantiated by the appearance of γH2AX foci upon Aphidicolin treatment or S-
associated hit knockdown (Figure 29). These results certify that the replication 






Figure 38. Checkpoint kinase activation. Protein levels of phosphorylated 
CHEK1 and CHEK2 upon treatment with replication inhibitor Aphidicolin and 
checkpoint inhibitor AZD7762. Experiments were done with the help of Dr Liang 
Hongqing. 
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B. Preservation of the pluripotency state by the ATM/ATR-CHEK2 axis 
We next inspected if checkpoint activation plays a dominant effect on 
suspending the exit from pluripotency. To accomplish this, checkpoint signalling was 
abolished in hESCs through the inhibition of ATM and ATR using Caffeine or RNAi. 
Under these conditions, pluripotency markers and NANOG-GFP fluorescence were 
downregulated upon withdrawal of self-renewal signals despite replication 
perturbation by Aphidicolin (Figure 39). Similarly, pan-inhibition of the effector 
kinases CHEKs rescued the exit from pluripotency from Aphidicolin (Figure 39C-D). 
Interestingly, knockdown of CHEK2 but not CHEK1 released the block on the exit 
from pluripotency (Figure 39A,B,D), suggesting that CHEK2 is the major effector of 
sustaining the pluripotent state.  
Since abolishment of the DNA replication checkpoint restored the ability of 
hESCs to exit the pluripotent state, we examined whether this also resulted in the 
restoration of cell cycle progression. In all these cases, inhibition of the DNA 
replication checkpoint pathway did not alter cell cycle profiles significantly (Figure 
40). With Aphidicolin, DNA replication remained largely delayed despite checkpoint 
abolishment (Figure 40), indicating that exit from pluripotency can be restored even 
though cell cycle progression remains halted. This excludes the possibility that cells 
are unable to differentiate as due to a simple S phase lock or the physical state of 
DNA during replication. These evidences from both genetic and chemical approaches 
independently validate our hypothesis that signalling through the ATM/ATR-CHEK2 








Figure 39. Effect of replication checkpoint inhibition on the exit from 
pluripotency. (A) Transcript levels of respective genes upon RNAi knockdown 
as measured by qPCR. All RNAi constructs effectively decreased expression of 
their target gene. (B-C) Expression levels of pluripotency markers upon (B) 
knockdown of replication checkpoint pathway members and (C) chemical 
inhibition of replication checkpoint signalling in the - bFGF, - TGFβ condition as 
measured by qPCR. All error bars denote standard deviation of triplicate data. (D) 
Representative images for NANOG-GFP fluorescence (green) and nuclear staining 
(blue) after inhibition of the replication checkpoint. Scale bar = 500μm. 
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During proliferation, stem cells can encounter various situations like 
replication stress, DNA damage and checkpoint activation. How stem cells make their 
fate choices in response to these special but prevalent cell cycle events have direct 
consequences on genome stability, tissue development and stem cell maintenance. 
From our experiments probing the exit from pluripotency upon DNA damage, we 
demonstrate that the pluripotent state is reinforced in the presence of replication stress 
via the ATM/ATR-CHEK2 axis. This is astonishing given that adult stem cells 
commit to differentiation upon checkpoint activation (Wang et al., 2012). We theorize 
that this could be a beneficial adaptation in hESCs because: (1) ESCs are known to 
express higher levels of homologous recombination and damage repair proteins (Roos 
et al., 2007; Tichy et al., 2010), which promotes resolution of DNA damage caused by 
replication stress, and (2) ESCs are able to enter apoptosis more efficiently in case the 
damage cannot be rectified, due to a lower apoptotic threshold in hESCs compared to 
differentiated cells (Dumitru et al., 2012; Liu et al., 2013). Hence, preservation of the 
pluripotent state in the presence of DNA damage decreases the chances of giving rise 
to a mutant progeny of differentiated cells.   
Figure 40. Cell cycle profile of hESCs upon abolishment of the replication 
checkpoint. Inhibition of the replication checkpoint pathway does not alter cell 
cycle progression as seen from flow cytometry quantification indicating the cell 
cycle profiles of hESCs. 
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C. Enhancement of TGFβ signalling by the DNA replication checkpoint 
To obtain a deeper mechanistic connection between ATM/ATR-CHEK2 
activation and pluripotency, we performed a time-course microarray analysis in 
hESCs treated with Aphidicolin and AZD7762. After 48 hours of Aphidicolin 
treatment, we observed upregulation of genes involved in cell cycle regulation, 
apoptosis and other housekeeping processes, as would be expected from induction of 
cell cycle arrest (Figure 41A,B). Notably, we also saw an upregulation of genes 
positively regulating TGFβ signalling and a simultaneous downregulation of BMP4 
pathway genes and TGFβ pathway antagonists (Figure 41A-C), which we validated 
by qPCR (Figure 41D). The TGFβ pathway has a well-known role in promoting the 
human pluripotent state (Beattie et al., 2005; Xu et al., 2008). Specifically, TGFβ 
signalling directly regulates NANOG transcription (Vallier et al., 2009; Xu et al., 
2008), which we observed to be upregulated following the changes in TGFβ-related 
gene expression (Figure 41C-E). Hence, this offers a potential explanation of how the 
ATM/ATR-CHEK2 axis could uphold pluripotency. 
Comparison of time-course expression levels demonstrated that TGFβ-related 
gene expression changes occur earlier and to a greater degree compared to the 
pluripotency marker expression changes that follow the withdrawal of self-renewal 
signals (Figure 41C-D). This confirms that the changes in TGFβ-related genes occur 
upstream of the pluripotency network. We also observed the same changes in TGFβ-
related gene expression upon stalling of DNA replication even when hESCs are in the 
pluripotency medium (Figure 41E), further validating the causative effect of DNA 
replication perturbation on TGFβ-related gene expression.  
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Importantly, these changes in TGFβ pathway gene expression lead to 
enhanced TGFβ signalling activation as indicated by increased SMAD2 
phosphorylation (Figure 42). Heightened TGFβ signalling can be reversed by 
treatment with AZD7762 (Figure 41, 42) without releasing stalled replication (Figure 
40), indicating that the ATM/ATR-CHEK2 axis directly augmented TGFβ signalling.  
Moreover, although TGFβ gene expression patterns are expected to change 
with cellular state, they do not simply correlate with pluripotency status (Figure 43). 
This again confirms that the changes in TGFβ pathway gene expression are a 




Figure 41. Time-course microarray analysis of replication checkpoint-
activated hESCs. (A-B) Gene ontology analysis. Enriched biological process 
terms (p<0.05) for (A) upregulated and (B) downregulated genes identified in the 
microarray analysis upon Aphidicolin (DNA polymerase inhibitor) treatment for 
48 hours in the - bFGF, - TGFβ condition. (C) Microarray heatmap for 
differentially expressed genes upon treatment with Aphidicolin and AZD7762 
(CHEK1/2 inhibitor) in the - bFGF, -TGFβ condition. (D) Time-course 
quantitative PCR for pluripotency and TGFβ-related genes upon treatment with 
Aphidicolin and AZD7762 in the - bFGF, - TGFβ condition. Error bars denote 
standard deviations of triplicate data. (E) Microarray heatmap for differentially 
expressed genes upon treatment with Aphidicolin and AZD7762 in pluripotency 
medium. Microarray experiments were done with the help of Yeo Jia-Chi. 




Collectively, these data strongly argue that in the presence of DNA replication 
perturbation, activation of the ATM/ATR-CHEK2 cascade alters expression of TGFβ-
related genes. This ultimately enhances TGFβ pathway signalling, which 
consequently sustains NANOG expression, preserves the hESC state and prevents the 
exit from pluripotency. Alteration of cytokine signalling pathways by the ATM/ATR-
CHEK2 axis is not farfetched, as it also regulates the interleukin-6 pathway in human 
fibroblasts (Rodier et al., 2009). Here we provide novel evidence that in hESCs, the 
ATM/ATR-CHEK2 axis uniquely affects the TGFβ pathway to regulate pluripotency. 
 
D. The role of p53 in the ATM/ATR-CHEK2-TGFβ cascade 
Given that the ATM/ATR-CHEK2 axis regulates the TGFβ pathway by 
regulating transcript levels of associated genes, we ought to determine the mediating 
factor by looking for transcription factors that satisfy two criteria: 1) it must act 
downstream of the ATM/ATR-CHEK2 axis and 2) it has binding sites near TGFβ-
related genes. We first examined p53, a key transcription factor activated downstream  
Figure 42. Phospho-SMAD2 levels during replication perturbation. Western 
blot of SMAD2 and phospho-SMAD2 from hESCs in the - bFGF, - TGFβ 
condition. SMAD2 phosphorylation is increased upon Aphidicolin (DNA 
polymerase inhibitor) treatment. Treatment with AZD7762 (CHEK1/2 inhibitor) 
prevents the increase in SMAD2 phosphorylation. Experiment was done with the 
help of Dr Liang Hongqing. 




of ATM/ATR-CHEK2 during DNA damage response (Banin et al., 1998; Hirao et al., 
2000; Tibbetts et al., 1999). A recent study performing chromatin 
immunoprecipitation with massively parallel tag sequencing (ChIP-Seq) for p53 
revealed binding sites near TGFβ-related genes in hESCs, albeit varied binding 
 
Figure 43. Comparison between changes in pluripotency and TGFβ-
associated gene expression. Expression levels of (A) pluripotency markers and 
(B) TGFβ agonists (color) and antagonists (grayscale) upon incubation either in 
pluripotency medium, in the - bFGF, - TGFβ condition, or in the - bFGF, - TGFβ 
followed by recovery in pluripotency medium. TGFβ-associated gene expression 
does not correlate with pluripotency marker expression. 
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depending on environmental conditions (Akdemir et al., 2014). Therefore, p53 could 
be the perfect candidate mediating ATM/ATR-CHEK2 with TGFβ signalling. 
We first confirmed that p53 is activated in this context by looking at p53 
protein levels. Both immunostaining and Western blot ascertain the upregulation of 
p53 levels upon DNA replication stalling of differentiating hESCs (Figure 44). 
Importantly, inhibition of the CHEK2 activity using AZD7762 reverted p53 levels, 
validating that the heightened p53 protein level is due to p53 stabilization by CHEK2 
(Hirao et al., 2000). 
We sought to determine if p53 activity is responsible for the effects of the 
ATM/ATR-CHEK2 axis on the exit from pluripotency by altering p53 levels in 







Figure 44. Expression levels of p53 in replication-perturbed hESCs. Protein 
levels of p53 as measured by (A) immunofluorescence staining (Scale bar = 
50μm) and (B) Western blot upon treatment with Aphidicolin (DNA replication 
inhibitor) and AZD7762 (CHEK1/2 inhibitor). Experiments were done with the 
help of Dr Liang Hongqing. 
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In this condition, p53 knockdown reversed the altered expression of TGFβ pathway 
genes, enabling downregulation of pluripotency markers (Figure 45). Thus, p53 
knockdown can overturn the effects of replication checkpoint activation, 
substantiating that p53 acts downstream of the ATM/ATR-CHEK2 axis in regulating 





Figure 45. Effect of p53 knockdown on the exit of pluripotency. (A) Transcript 
levels of p53 upon RNAi knockdown as measured by qPCR. Both RNAi 
constructs effectively decreased expression of p53. (B-C) Expression levels of (B) 
TGFβ agonists (color) and antagonists (grayscale) and (C) pluripotency markers 
upon p53 knockdown in the - bFGF, - TGFβ condition with Aphidicolin (DNA 
polymerase inhibitor). Experiments were done with the help of Dr Liang 
Hongqing. 
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To test whether p53 alone is sufficient to enhance the TGFβ signalling 
pathway in hESCs, we activated p53 in the absence of DNA replication stalling using 
the small molecule Nutlin-3, which prevents p53 degradation by inhibiting the 
interaction of p53 with MDM2 (Vassilev et al., 2004), similar to CHEK2’s 
mechanism (Hirao et al., 2000). Nutlin-3 effectively increased p53 levels in hESCs 
(Figure 46A-B), which led to the alteration of TGFβ signalling pathway gene 







Figure 46. Effect of Nutlin-3 treatment on the exit of pluripotency. (A-B)  
Protein levels of p53 as measured by (A) immunofluorescence staining (Scale bar 
= 50μm) and (B) Western blot upon treatment of hESCs with Nutlin-3 (p53 
stabilizer). (C-D) Expression levels of (C) TGFβ agonists (color) and antagonists 
(grayscale) and (D) pluripotency markers upon Nutlin-3 treatment. Experiments 
were done with the help of Dr Liang Hongqing. 
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46C). Accordingly, this resulted in delayed exit from pluripotency (Figure 46D), 
confirming that p53 alone can attenuate the exit from pluripotency by modulating the 
expression of TGFβ-related genes. 
Altogether, our results prove that p53 enforces the prevention of the exit from 
pluripotency following DNA replication perturbation.  This is surprising given that 
current literature assigns p53 as a factor opposing both the maintenance and 
acquisition of the pluripotent state (Hong et al., 2009; Jain et al., 2012; Kawamura et 
al., 2009; Li et al., 2012b; Lin et al., 2005; Qin et al., 2007), which seemingly 
contradicts our findings. However, it is important to note that as a hub transcription 
factor, p53 is known to regulate different gene sets (Akdemir et al., 2014) and mediate 
diverse cell fate transitions under different cellular contexts (Chang et al., 2011; Ubil 
et al., 2014). On top of that, different p53 activation dynamics under similar contexts 
can even trigger distinct outcomes (Aylon and Oren, 2007; Lee et al., 2010). Hitherto, 
p53 activity has not been studied in the context where both differentiation cues and 
DNA damage cues are present. Now we show that in this context, p53 switches to a 
role that upholds the human pluripotent state by enhancing TGFβ signalling, again 
emphasizing the importance of studying regulatory mechanisms within specific 
contexts.  
 
We therefore propose a model of how perturbation of DNA replication during the S 
phase prevents the exit from pluripotency (Figure 47). Stalled DNA replication leads 
to the activation of the DNA replication checkpoint, initiated by ATM and ATR. 
These kinases phosphorylate CHEK2, which in turn, stabilizes p53 protein. p53 then 
binds to the chromatin and upregulates the transcription of TGFβ agonists while 
downregulating TGFβ antagonist expression. These changes in TGFβ-related gene 
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expression synergize to enhance pathway transduction. Finally, enhanced TGFβ 






Figure 47. The role of the DNA replication checkpoint in the exit from 
pluripotency. Perturbation of DNA replication during the S phase of hESCs lead 
to the activation of the DNA replication checkpoint, initiated by the ATR and 
ATM sensor kinases. These phosphorylate and activate CHEK2, which in turn 
stabilizes p53. p53 then activates transcription of TGFβ agonists and repress 
TGFβ antagonists. These transcriptional changes work to enhance TGFβ 
signalling, SMAD2 phosphorylation and NANOG transcription, ultimately 
supporting the pluripotent state. 
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IX. Cyclin B1 upholds the pluripotent state during the G2 phase 
While the mechanism above explains how cell cycle perturbations in the S 
phase prevents the exit from pluripotency, it cannot explain how arrest at the G2 
phase provides the same effect. To find the mechanism underlying the G2 phase’s role 
in the exit from pluripotency, we started by looking for factors or pathways that get 
upregulated during perturbation at the G2 phase of hESCs, starting with the cyclins. 
We observed that knockdown of G2-associated hits resulted in a prolonged G2 phase 
(Figure 30) concomitant with elevated expression of Cyclin B1, but not other cyclins 
(Figure 48). We therefore focused on whether Cyclin B1 plays a role in preserving the 






Figure 48. Cyclin levels upon knockdown of G2-associated hits. Western blot 
of Cyclins D1, A2, E1 and B1 upon knockdown of G2-associated hits in hESCs. 
Only Cyclin B1 shows a consistent upregulation amongst samples. 
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A. Exit from pluripotency by Cyclin B1 knockdown 
To test if Cyclin B1 plays a role in promoting the pluripotent state, we 
ectopically modified expression levels of Cyclin B1 in hESCs. Knockdown of Cyclin 
B1 (Figure 49A) caused a dramatic downregulation of pluripotency marker expression 
prior to cell death (Figure 49B-C). Cyclin B1 knockdown also induced a prolongation 
of the G2 phase and a shortening of the G1 phase (Figure 49D-E), similar to other G2-
specific factors (Figure 30). This is intriguing as knockdown of other G2-specific 
factors led to the preservation of pluripotency (Figure 20B), but Cyclin B1 
knockdown caused the opposite. In addition, the concomitant differentiation and G1 
shortening caused by Cyclin B1 knockdown demonstrates a decoupling of the 
expected cell cycle profile associated with differentiation. These deviations imply that 
the effects of Cyclin B1 on pluripotency are downstream of G2 phase arrest and 
indicate a tight linkage between Cyclin B1 and pluripotency. 
 
B. Preservation of the pluripotent state by Cyclin B1 overexpression 
To further validate whether Cyclin B1 is the underlying factor for the 
causative effect of a prolonged G2 phase in blocking exit from pluripotency, we 
overexpressed Cyclin B1 in hESCs (Figure 50A) and demonstrated for the first time 
that overexpression of a single cell cycle factor can attenuate the exit from 
pluripotency (Figure 50B-C). Moreover, this overexpression of Cyclin B1 did not 
cause significant enrichment of cells in the G2 phase (Figure 50D-E), indicating that a 
prolongation of the G2 phase is not necessary for Cyclin B1 to preserve the 
pluripotent state. Altogether, these results reveal that Cyclin B1 is the cardinal 
connecting node between the G2 phase and its ability to prevent the exit from 
pluripotency.  




Figure 49. Effect of Cyclin B1 knockdown on pluripotency. (A) Transcript 
levels of CCNB1 upon RNAi knockdown as measured by qPCR. Both RNAi 
constructs effectively decreased expression of p53. (B) Representative images for 
NANOG-GFP fluorescence (green) and nuclear staining (blue) after CCNB1 
knockdown in the pluripotency medium. Scale bar = 500μm. (C) Expression 
levels of pluripotency markers upon CCNB1 knockdown in the pluripotency 
medium. (D) Flow cytometry profiles and (E) flow cytometry quantification 
indicating the cell cycle status of hESCs after CCNB1 knockdown in the 
pluripotency medium.  







Figure 50. Effect of Cyclin B1 overexpression on the exit from pluripotency. 
(A) Protein levels of Cyclin B1 upon overexpression as measured by Western 
blot. (B) Representative images for NANOG-GFP fluorescence (green) and 
nuclear staining (blue) after CCNB1 overexpression in the - bFGF, - TGFβ 
condition. Scale bar = 500μm. (C) Expression levels of pluripotency markers 
upon CCNB1 overexpression in the - bFGF, - TGFβ condition. (D) Flow 
cytometry profiles and (E) flow cytometry quantification indicating the cell cycle 
status of hESCs after CCNB1 overexpression in the pluripotency medium. 
Experiments were done with the help of Dr Liang Hongqing. 
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C. Possible mechanisms behind the role of Cyclin B1 in the exit from pluripotency 
To investigate how Cyclin B1 promotes the pluripotent state, we performed a 
time-course microarray analysis of hESCs overexpressing Cyclin B1. Interestingly, 
we also found an upregulated expression of TGFβ agonists, concomitant with the 
preservation of pluripotency marker expression (Figure 51A-B). Therefore, Cyclin B1 
might also work through the TGFβ pathway to prevent the exit from pluripotency. 
Notably, Cyclin B1 overexpression also resulted in decreased expression of genes 
involved in specification of neuroectodermic lineages and an opposite trend for 
mesodermic lineages (Figure 51C), suggesting that Cyclin B1 might supplement its 
role in the exit from pluripotency by keeping the balance in expression of lineage-
specifying genes (Loh and Lim, 2011).  
Finally, we checked if Cyclin B1 activity is dependent on its partner kinase 
CDK1. Surprisingly, when CDK1 is knocked down while self-renewal signals were 
withdrawn, the exit from pluripotency is prevented, similar to other G2-associated 
factors (Figure 52A-C). Inhibition of CDK1 with RO3306 had the same effect (Figure 
52A,D). This indicates that while CDK1’s effect on the exit from pluripotency could 
be dependent on Cyclin B1, Cyclin B1’s functions on pluripotency are downstream of 
and autonomous from CDK1. This is very intriguing as Cyclin B1 is not yet known to 
have CDK-independent functions. Interestingly, the G1 phase-associated Cyclin D1 
has been demonstrated in mice to have a role in regulating transcription independent 
of its CDK partners (Bienvenu et al., 2010). It is possible that Cyclin B1 has adopted 








Figure 51. Time-course microarray analysis upon Cyclin B1 overexpression 
in hESCs. (A) Microarray heatmap for differentially expressed genes upon 
overexpression of Cyclin B1 in the - bFGF, -TGFβ condition. (B) Time-course 
quantitative PCR for pluripotency and TGFβ-related genes upon overexpression 
of Cyclin B1 in the - bFGF, - TGFβ condition. Error bars denote standard 
deviations of triplicate data. (C) Gene ontology analysis. Enriched biological 
process terms (p<0.05) for upregulated and downregulated genes identified in the 
microarray analysis upon Cyclin B1 overexpression in the - bFGF, - TGFβ 






Figure 52. Effect of CDK1 inhibition on the exit from pluripotency. (A) 
Representative images for NANOG-GFP fluorescence (green) and nuclear staining 
(blue) after CDK1 inhibition. Scale bar = 500μm. (B) Transcript levels of CDK1 
upon RNAi knockdown as measured by qPCR. Both RNAi constructs effectively 
decreased expression of CDK1. (C-D) Expression levels of pluripotency markers 
of hESCs in the - bFGF, - TGFβ condition upon (C) CDK1 knockdown or (D) 




D. Role of other cyclins in the exit from pluripotency 
We finally examined whether these effects are exclusive to the G2/M-specific 
Cyclin B1 or if it can be conferred by other cyclins as well. Modulation of expression 
levels of Cyclins A2 and D1 neither induced nor prevented the exit from pluripotency 
(Figure 53,54). Surprisingly, knockdown of Cyclin E1 caused downregulation of 






Figure 53. Effect of knockdown of other cyclins on pluripotency. (A) Protein 
levels of Cyclins A2, D1 and E1 upon RNAi knockdown as measured by Western 
blot. (B) Representative images for NANOG-GFP fluorescence (green) and 
nuclear staining (blue) after cyclin knockdown in the pluripotency medium. Scale 
bar = 500μm. (C) Expression levels of pluripotency markers upon cyclin 




pluripotency (Figure 53,54). Thus, Cyclin E1 has the same effects on the exit from 
pluripotency to that of Cyclin B1. As Cyclin E1 is expressed at the G1/S interface, 
this factor could provide an additional route from cell cycle stalling at the S phase 
could act to preserve the pluripotent state.   







Figure 54. Effect of overexpression of other cyclins on the exit from 
pluripotency. (A) Protein levels of Cyclins A2, D1 and E1 upon overexpression 
as measured by Western blot. (B) Representative images for NANOG-GFP 
fluorescence (green) and nuclear staining (blue) after cyclin overexpression in the 
- bFGF, - TGFβ condition. Scale bar = 500μm. (C) Expression levels of 
pluripotency markers upon cyclin overexpression in the - bFGF, - TGFβ 




In a broader perspective, these results demonstrate that cyclins not only act as 
the major regulators of cell cycle progression (Evans et al., 1983; Pines, 1991), but 
also influence other biological processes unrelated to the cell cycle. In fact, cyclins 
have been implicated in various processes including transcription, DNA damage 
response, epigenetic regulation and lipogenesis (Lim and Kaldis, 2013). A role for 
cyclins in other cellular functions inevitably couples these processes to the cell cycle, 
contributing to the distinct cell states that are represented by the different cell cycle 
phases. While the results here only refer to the regulation of pluripotency exit, it is 
likely that similar mechanisms are in place for other biological processes, calling for 
future studies to extensively characterize the non-classical roles of cyclins, which may 
even be CDK-independent, as we have demonstrated for Cyclin B1. 
 
Altogether, these results indicate that Cyclin B1 is the key mediator for upholding the 
pluripotent state during the G2 phase. Although further experiments need to be done 
to conclusively understand its mechanism, we performed preliminary analyses hinting 
that Cyclin B1 could partially work through the TGFβ pathway, and by managing the 









Figure 55. The role of Cyclin B1 in the exit from pluripotency. Arrest of cell 
cycle progression at the G2 phase leads to the accumulation of Cyclin B1. 
Heightened Cyclin B1 levels induce transcriptional changes that enhance TGFβ 
signalling and maintain the balance of lineage-specifying genes, both of which 





The exit from pluripotency necessitates the collapse of the pluripotency 
network. Yet, how differentiation cues lead to the breakdown of this network is ill-
defined, especially in hESCs. We performed a systematic large-scale RNAi screen 
under multiple differentiation conditions to unveil genes required for this process. Our 
systematic functional screens of hESCs under multiple differentiation conditions 
enabled the identification of both universal and specific regulatory axes for the exit 
from pluripotency (Figure 56). Our results thus provide insight on how some 
regulatory modules have conserved functions regardless of other cues, while others 
perform in a very context-specific manner. Members of chromatin-modifying 
complexes such as HAT complexes and the SWI/SNF complex were highly enriched, 
emphasizing a universal need to restructure the chromatin to enable complete cell fate 
transition during PSD. Conversely, other PSD regulators like development-related 
signalling pathways and RNA splicing tend to function in a more context-dependent 
manner. Altogether, the results of the large-scale RNAi screen presented in this thesis 
delivers a unique resource for dissecting the mechanisms behind PSD by providing 
new insight on the roles of various factors and pathways on PSD and opens the 
avenue for future work on unravelling the complete regulatory network of this 
process. 
Moreover, the data presented in this thesis address the unanswered question of 
whether factors in the core cell cycle machinery enforce a deterministic regulation on 








stimulated during S and G2 phase perturbation play an active role in promoting the 
pluripotent state and preventing its exit (Figure 57). Specifically, we find the 
ATM/ATR-CHEK2-p53 axis in the S phase and Cyclin B1 in the G2 phase 
functioning to uphold the hESC state.  Such a direct linkage from S- and G2-specific 
pathways to the exit from pluripotency has not been reported before, thus introducing 
a new paradigm for the coupling of cell cycle and pluripotency. In contrast, we did 
not find G1-specific factors implicated in differentiation to have an effect on the exit 
from pluripotency in this context. Instead, our results suggest that the G1 phase is 
amenable to the exit from pluripotency because of the absence of such pathways that 
actively preserve hESC identity. Finally, as the ATR/ATM-mediated checkpoint can 
be activated by endogenous damage generated during DNA replication and Cyclin B1 
is more abundant during the G2 phase of the unperturbed cell cycle, these pathways 
and their effects in upholding pluripotency can be applied to normal progression 





Figure 56. Summary of high-throughput RNAi screen. High-throughput RNAi 
screening in multiple differentiation conditions enabled the identification of 






ESCs display a unique cell cycle profile with a shortened G1 phase (Coronado 
et al., 2013; Hindley and Philpott, 2013; Singh and Dalton, 2009; Stead et al., 2002). 
This was thought to maintain pluripotency by limiting time spent in the G1 phase, 
which is the only phase permissive to differentiation (Mummery et al., 1987; Pauklin 
and Vallier, 2013; Sela et al., 2012). However, there is little evidence to 
unambiguously declare that the cell cycle phases can dominantly and deterministically 
 
Figure 57. Outline of mechanisms behind the prevention of the exit from 
pluripotency in the S and G2 phases. hESCs resist the exit from pluripotency 
during the S and G2 phases due to the presence of active mechanisms that uphold 




regulate the pluripotency network. In this thesis, we show that the S and G2 phases 
employ specific pathways to actively boost the pluripotent state, rather than just 
passively retain the pluripotent state in the absence of the G1 phase’s effects. In fact, 
our results imply that it is the absence of such pathways in the G1 phase that underlies 
its responsiveness to differentiation cues. The need to actively boost the pluripotent 
state may be critical given the fact that the inclination of the G1 phase towards 
differentiation may lead to a transient tendency for pluripotency decay every time 
cells pass through it. Therefore, active resumption of the pluripotency network in the 
following S and G2 phases may be critical to tilt the cell fate balance back to 
pluripotent state maintenance. Thus, the results in this thesis can be culminated in a 
proposed model wherein the S/G2 and M/G1 phases shift the weights between 
pluripotency maintenance and exit across the hES cell cycle (Figure 58). This model 
suggests that a balance between cell cycle phases is critical for ESC fate 




Figure 58. Model of how pluripotency maintenance and exit is regulated by a 
balance between the different cell cycle phases. Active pathways in the S and 
G2 phases promote the pluripotent state, enforcing maintenance of hESC identity. 
Conversely, hESCs are primed for the exit from pluripotency at the G1 and M 
phases due to the absence of such pathways. Cell cycle progression alternates 
between these two states, enabling both self-renewal and ability to differentiate.  
 110 
 
While these findings provide answers to the fundamental question of whether 
the cell cycle machinery directly regulates the exit from pluripotency in hESCs, they 
also open up new questions for future research. First, it is imperative to find out 
whether the observed cell cycle-dependent restriction of cell fate transition in hESCs 
is also applicable to other undifferentiated cell types such as adult stem cells and 
cancer cells, and if so, whether the underlying mechanisms are conserved or not. 
Second, as our results prove that cell cycle manipulations in hESCs can influence cell 
fate transitions, this knowledge can be applied to improve the efficiency of directed 
differentiation protocols. Finally, given the complexity of cell cycle regulation, it is 
almost certain that there are additional mechanisms in place for the effects of the cell 
cycle on the exit from pluripotency, besides the ones shown in this thesis. Therefore, 
this pilot study jumpstarts the search for more connective nodes between the cell 
cycle machinery and pluripotency. 
 In conclusion, this thesis summarizes the results of our studies, which 
contribute to the understanding of the exit from pluripotency in hESCs, and how this 
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Appendix 1. List of qPCR primers 









































































































































Appendix 2. List of RNAi sequences 


































MCM5 CTGAAGTCGGACATGATGT ACGTGAGCGCACTGACACA 
ORC1L GCTTCACCTGAACATCGCA CAGAGATTTCAGACTCTAG 
GMNN GAGCTAATAGAGAGACTGA GTATATGGCAGAGCTAATA 
CCDC6 CAGTGTTGTGGGTCTACAA GCAACAGTCCTGACAAATTC
A 









































































Appendix 3. List of hits in the - bFGF, - TGFβ condition 
Gene Symbol Entrez Gene ID Mean Z-score Mean Cell Viability Score 
SMARCA5 8467 5.869282 0.839829 
ACTL6A 86 5.483016 0.161976 
CCDC6 8030 5.460845 0.982402 
DDX6 1656 4.9581 0.308243 
KAT5 10524 4.420716 0.259281 
CNOT2 4848 4.326923 0.364522 
CNOT3 4849 4.318167 0.542582 
ENY2 56943 3.597846 0.854299 
HSF1 3297 3.528116 0.865967 
POLR1A 25885 3.166428 0.160843 
SETD2 29072 3.035043 0.577263 
NOC2L 26155 3.022793 0.190277 
TADA3 10474 2.989501 1.159938 
MEAF6 64769 2.884428 0.502794 
PRPF4B 8899 2.87604 0.730647 
ILF3 3609 2.82386 0.267254 
DHX16 8449 2.785978 0.247583 
BARD1 580 2.75891 0.357742 
SMARCC1 6599 2.738959 0.549892 
TSG101 7251 2.651138 0.292815 
ZNF140 7699 2.620046 0.794513 
CSNK1A1 1452 2.612363 0.82705 
MAX 4149 2.594695 0.674808 
NAT10 55226 2.570848 0.322444 
GABPB1 2553 2.529705 0.317756 
RXRA 6256 2.524585 0.455905 
CHD3 1107 2.447744 0.225399 
BPTF 2186 2.282481 0.887256 
RARB 5915 2.276966 0.396075 
ZNRF1 84937 2.270899 1.291893 
BUB1 699 2.270332 0.704695 
FOXC2 2303 2.242375 0.357211 
TRIB3 57761 2.234426 0.595736 
ZNF860 344787 2.222835 0.621504 
PHF12 57649 2.201726 0.922017 
CDC2 983 2.18586 0.880317 
HIST1H2BE 8344 2.170879 0.372116 
UNCX 340260 2.143311 0.611737 
RBM7 10179 2.136006 0.462185 
PATZ1 23598 2.031076 0.329792 
SMARCA4 6597 1.968374 0.302959 
GPR4 2828 1.89507 0.913843 
 130 
 
SKIL 6498 1.880279 1.119721 
HIST1H1C 3006 1.776697 0.641745 
LOC91461 91461 1.666532 0.925055 
PPP1R12A 4659 1.595832 0.895704 
GPR22 2845 1.465623 0.844729 
YEATS2 55689 2.762648 0.307423 
DMAP1 55929 2.641341 0.248067 
ILF2 3608 2.598684 0.208361 
CHD8 57680 2.595751 0.544948 
DHX37 57647 2.589043 0.265184 
MAZ 4150 2.573902 0.577391 
NFKB2 4791 2.566391 0.580524 
ESPL1 9700 2.531161 0.231478 
NR2C2 7182 2.454664 0.382861 
C20orf20 55257 2.441838 0.606945 
LAS1L 81887 2.426053 0.273103 
BRD8 10902 2.383031 0.641544 
SNIP1 79753 2.37501 0.248388 
TRRAP 8295 2.358355 0.352415 
ZIC3 7547 2.346794 0.484757 
C11orf30 56946 2.300292 1.133289 
CDC2L2 728642 2.281274 0.200104 
CRK7 51755 2.275951 0.877251 
CSNK2B 1460 2.187604 0.858716 
FUS 2521 2.149051 0.83369 
EIF5B 9669 2.132064 0.223154 
SAP18 10284 2.118492 0.274155 
CIC 23152 2.09946 0.482677 
KAT2A 2648 2.094975 0.8386 
ZBTB12 221527 2.092462 1.102796 
PYGO1 26108 2.082673 0.282389 
DPF2 5977 2.048047 0.342108 
COPS5 10987 2.047223 0.30076 
TCF7L1 83439 2.035807 0.338124 
ETV5 2119 2.028036 0.379003 
EXOSC10 5394 2.015847 0.546531 
ZNHIT6 54680 1.992057 0.54084 
RBMX 27316 1.989799 0.304618 
BRCA2 675 1.987551 0.282202 
MTF1 4520 1.982405 0.558391 
EYA1 2138 1.975624 0.174405 
CDC25A 993 1.958147 0.800849 
TPR 7175 1.943308 0.52714 
SMARCE1 6605 1.932042 0.508457 
 131 
 
ORC1L 4998 1.930002 0.428054 
OPN3 23596 1.920588 0.834964 
GMNN 51053 1.91049 0.312537 
SIN3B 23309 1.908024 0.740513 
AURKA 6790 1.893505 0.963257 
BARX1 56033 1.890243 0.28115 
AHRR 57491 1.84469 0.172904 
CCT4 10575 1.842673 0.282939 
ARID1A 8289 1.833016 0.437272 
MYEOV2 150678 1.814735 0.759619 
MBD3 53615 1.814098 0.539505 
WDR77 79084 1.807729 0.553592 
YY1 7528 1.80516 0.160275 
SETD8 387893 1.801512 0.187206 
SFRS6 6431 1.799853 0.842518 
ZSCAN12 9753 1.799274 0.493184 
H2AFZ 3015 1.793877 0.578258 
KLHL41 10324 1.793181 0.78237 
GMEB1 10691 1.774919 0.638417 
OGT 8473 1.772843 0.636149 
MDM4 4194 1.762111 0.452708 
KIAA1310 55683 1.757319 0.01651 
TSPYL3 128854 1.749925 1.172408 
CETN2 1069 1.727207 0.922015 
KLHL14 57565 1.721915 0.697751 
RBBP4 5928 1.709623 0.246354 
ATXN2 6311 1.706602 0.926146 
BTAF1 9044 1.701417 0.934329 
ZMYND8 23613 1.698474 0.971272 
DIDO1 11083 1.691884 0.405602 
PROP1 5626 1.660303 0.267848 
TCF23 150921 1.630527 0.610948 
GPR147 64106 1.624486 0.630393 
NRF1 4899 1.621229 0.248604 
MC3R 4159 1.621174 0.501381 
IL13 3596 1.603541 0.475624 
TBX1 6899 1.60115 0.963401 
DDX27 55661 1.597007 0.258032 
HTT 3064 1.594034 1.113343 
C12orf41 54934 1.582244 0.43316 
ZNF48 197407 1.578245 0.691743 
GON4L 54856 1.578158 1.230509 
TFDP2 7029 1.566201 0.949364 
ROCK1 6093 1.561698 0.839824 
 132 
 
CASP2 835 1.555531 0.562889 
TACR2 6865 1.553305 0.744828 
CBFA2T3 863 1.551773 0.327733 
ZDHHC1 29800 1.543371 0.804975 
TCEB2 6923 1.541395 0.305174 
THAP11 57215 1.540047 0.94406 
JARID2 3720 1.536811 0.7062 
ARID3B 10620 1.534729 0.439162 
NAGK 55577 1.532449 0.969585 
TIGD4 201798 1.506258 1.245067 
AIP 9049 1.506237 0.124029 
SVEP1 79987 1.501175 0.38907 
CDK8 1024 1.479287 0.94925 
IRF2 3660 1.475936 0.857523 
MMP9 4318 1.475932 0.329346 
SETMAR 6419 1.457933 0.071716 
NTRK2 4915 1.457137 0.984119 
YBX1 4904 1.44806 0.418119 
NFKBIL2 4796 1.447428 0.531313 
EMX1 2016 1.437284 0.449538 
TFAP2B 7021 1.430711 0.810662 
ATG4B 23192 1.417206 0.860999 
WBP11 51729 1.416754 0.391203 
DDX19A 55308 1.407622 0.947153 
EP400 57634 1.400543 0.329437 
TIMM50 92609 1.397515 0.888602 
BPNT1 10380 1.3933 0.929577 
ZNF324 25799 1.388203 0.614092 
FIGLA 344018 1.387577 0.485383 
TICRR 90381 1.382642 0.500659 
NUDT21 11051 1.378719 0.196149 
STON1 11037 1.377385 0.78346 
BIRC5 332 1.373331 0.266309 
PCNA 5111 1.372453 0.265116 
DRAP1 10589 1.371026 1.161495 
ZNF70 7621 1.369033 0.941417 
PPP1CA 5499 1.368785 0.348042 
SRCAP 10847 1.366842 0.172093 
DUSP6 1848 1.348194 0.885348 
DUSP10 11221 1.336001 0.774118 
PDX1 3651 1.326863 0.803294 
DPF1 8193 1.31987 0.466464 
DR1 1810 1.308609 1.109319 
DHX58 79132 1.307035 0.556235 
 133 
 
ZNF574 64763 1.300668 0.109876 
GPR153 387509 1.299487 0.860915 
MCM5 4174 1.278632 0.416658 
ASB12 142689 1.276394 0.377423 
RAP1GAP 5909 1.274286 0.916226 
FFAR1 2864 1.265985 0.951375 
OTX2 5015 1.244985 0.561147 
UMPK 7371 1.244717 1.04597 
DHX9 1660 1.233013 0.294378 
HES2 54626 1.229457 0.562685 
NUP62 23636 1.215847 0.766179 
GPR156 165829 1.206866 0.872205 
CDKL3 51265 1.205719 0.997066 
DMRTB1 63948 1.201494 0.249506 
PTGFR 5737 1.199582 0.895978 
NEK1 4750 1.193928 0.911078 
IRAK2 3656 1.189881 0.97351 
NKAP 79576 1.185625 0.289486 
HELZ 9931 1.185075 0.723814 
ZFP3 124961 1.177928 0.216375 
EDG5 9294 1.167201 0.880713 
PTEN 5728 1.141416 0.928846 
CHMP6 79643 1.106687 0.707924 
FUK 197258 1.100659 0.995415 
ZNF467 168544 1.100314 0.417385 
PTRF 284119 1.082397 0.775244 
GPR12 2835 1.079001 0.947832 
NT5C 30833 0.988326 0.809417 
ZIC4 84107 0.943337 0.570531 
IKBKAP 8518 0.935737 0.796106 
SPEN 23013 0.752955 0.191599 





Appendix 4. List of hits for the TGFβ pathway inhibition condition 
Gene Symbol Entrez Gene ID Mean Z-score Mean Cell Viability Score 
KAT5 10524 8.500555 0.093213 
SMARCA5 8467 7.834006 0.251136 
DDX6 1656 7.306216 0.940609 
TADA3 10474 6.822607 0.724203 
MAX 4149 5.972157 0.461944 
CCDC6 8030 5.168458 0.116037 
SETD2 29072 4.687285 0.504832 
TRRAP 8295 4.522646 0.037156 
CIC 23152 4.394846 0.158667 
CNOT2 4848 4.061287 0.096676 
SKIL 6498 3.850636 0.448934 
HSF1 3297 3.706731 0.080219 
AIP1 9863 3.702754 0.001365 
SOX11 6664 3.674094 1.040297 
AOF2 23028 3.43429 0.239363 
ZMYND8 23613 3.317655 0.533291 
BRD4 23476 3.263565 0.107031 
EP400 57634 3.255099 0.042811 
PIK3R2 5296 3.199677 0.001781 
HELT 391723 3.10906 0.563268 
ENY2 56943 3.108157 0.546719 
KDM5B 10765 3.097936 0.110372 
CNOT3 4849 3.088913 0.109915 
ZBTB12 221527 3.048454 0.499277 
DNMT1 1786 2.969742 0.167631 
SKI 6497 2.819455 0.552766 
STON1 11037 2.80089 0.038367 
RSF1 51773 2.736912 0.387407 
LSM12 124801 2.730703 0.239472 
NFYC 4802 2.710035 0.504298 
XRCC3 7517 2.700963 0.163053 
ZBTB39 9880 2.66349 0.843745 
ZNF287 57336 2.657818 0.222059 
MAF1 84232 2.657211 0.074596 
PTGS2 5743 2.593612 0.271994 
HIST1H2AK 8330 2.479352 0.225366 
ZNF846 162993 2.460631 0.088816 
ZBTB46 140685 2.455202 0.172015 
ZNF140 7699 2.443684 0.093163 
BAZ1B 9031 2.434823 0.632911 
ZNRF1 84937 2.42661 0.232081 
TIGD4 201798 2.419531 0.337323 
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ZNF689 115509 2.400125 0.35854 
TFDP2 7029 2.367838 0.107992 
PPP1CC 5501 2.363951 0.00525 
EED 8726 2.354056 0.61863 
UBN1 29855 2.343187 0.154717 
SMARCE1 6605 2.334844 0.135732 
SETD5 55209 2.302616 0.082448 
CDC2 983 2.249203 0.08773 
RAI14 26064 2.23928 0.402841 
NIPBL 25836 2.193568 0.03373 
DHX58 79132 2.188633 0.089407 
SMAD4 4089 2.164124 1.018242 
ZNF69 7620 2.156333 0.255653 
HTT 3064 2.14767 0.560795 
JMJD7-
PLA2G4B 
8681 2.133011 0.688662 
TOX4 9878 2.127174 0.832769 
NUP62 23636 2.113548 0.002104 
NFYB 4801 2.106238 1.07298 
DFFB 1677 2.086489 0.572511 
ZIC3 7547 2.085392 0.088481 
MZF1 7593 2.07303 0.004678 
IL13 3596 2.043556 0.145339 
CDC2L2 728642 2.040397 0.002263 
MEIS1 4211 2.037857 0.418983 
L3MBTL2 83746 2.035535 0.084081 
GMEB1 10691 2.003581 0.169052 
DPF2 5977 1.994861 0.036312 
BPTF 2186 1.988137 0.176727 
UBP1 7342 1.985456 0.51958 
CHD1L 9557 1.952948 0.993246 
HIST1H1A 3024 1.952727 0.179962 
HIST1H1C 3006 1.943209 0.051822 
ZMYM2 7750 1.929547 0.306278 
MCM8 84515 1.927351 0.017134 
ZNF793 390927 1.925971 0.51161 
SUPT20H 55578 1.915236 0.266075 
SRRM1 10250 1.913023 0.087678 
ZNF354C 30832 1.903431 0.553552 
VEGFA 7422 1.858479 0.289521 
ZNF423 23090 1.855819 0.152005 
ZNF695 57116 1.849036 0.221648 
ADORA1 134 1.847487 0.295649 
ZNF92 168374 1.838197 0.658696 
ACIN1 22985 1.831692 0.773224 
 136 
 
ATG7 10533 1.799631 0.261506 
HKR1 284459 1.783316 0.760659 
CDC2L1 984 1.77972 0.00845 
SIN3B 23309 1.773454 0.530537 
UBTF 7343 1.771513 0.072984 
ZIC5 85416 1.757049 0.208026 
ZNF432 9668 1.741552 0.489139 
MLNR 2862 1.733637 0.121295 
FLJ34389 197259 1.727372 0.161107 
CREB1 1385 1.720396 0.391923 
ZNF671 79891 1.720267 0.504045 
NDN 4692 1.710066 0.096457 
TRIB3 57761 1.708707 0.010218 
PLK1 5347 1.697705 0.002944 
RBKS 64080 1.695117 0.402948 
GPRC5B 51704 1.685528 0.036406 
WEE1 7465 1.681142 0.004052 
BTAF1 9044 1.681116 0.180609 
LSM14A 26065 1.679036 0.114269 
ARID2 196528 1.676843 1.328193 
ZIC1 7545 1.675335 0.193986 
RABGAP1L 9910 1.651894 0.655652 
ZNF27 0 1.629934 0.611814 
CSNK2A1 1457 1.622431 0.594907 
GON4L 54856 1.619349 0.056148 
EGR3 1960 1.617023 0.458048 
ASCL3 56676 1.61609 0.172599 
KLHDC3 116138 1.615708 0.662741 
PPARGC1B 133522 1.595375 0.187351 
AURKA 6790 1.584807 0.056916 
KLF4 9314 1.576385 0.287166 
ZNF668 79759 1.574289 0.312597 
KAT2A 2648 1.574077 0.563696 
PTPN12 5782 1.565333 0.401493 
MAPT 4137 1.559559 0.054902 
UBE2K 3093 1.545062 0.945313 
TCF7L2 6934 1.54139 0.89919 
CNOT1 23019 1.518457 0.00741 
SCML4 256380 1.512091 0.14198 
IL24 11009 1.487028 0.512251 
LOC91461 91461 1.481985 0.004375 
KIAA2002 79834 1.44217 0.646311 
MGA 23269 1.441326 0.277095 
AMD1 262 1.4321 0.058278 
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TESK1 7016 1.421965 0.442114 
PBX4 80714 1.412995 0.261229 
HOPX 84525 1.412908 0.082224 
MTF1 4520 1.40846 0.470873 
MC3R 4159 1.383325 0.006231 
DUSP6 1848 1.376909 0.041479 
TACR2 6865 1.364175 0.016701 
RBFOX2 23543 1.278169 0.49135 
HIRA 7290 1.269069 0.148656 
CBFA2T3 863 1.26127 0.021579 
LTB4R 1241 1.238326 0.246107 
CRK7 51755 1.227744 0.131756 
ZIC2 7546 1.212511 0.14526 
RBMX 27316 1.105143 0.009703 
VHL 7428 1.071208 0.045267 
WBP11 51729 1.046851 0.004631 
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Appendix 5. List of hits for the bFGF pathway inhibition condition 
Gene Symbol Entrez Gene ID Mean Z-score Mean Cell Viability Score 
PIK3R2 5296 7.619988 0.003103 
CDC2L2 728642 5.322273 0.006151 
PSMC5 5705 4.994384 0.020127 
KAT5 10524 4.862223 0.286129 
PVR 5817 4.860288 0.022833 
RBMX 27316 4.284094 0.417923 
MC3R 4159 3.997967 0.015429 
EP400 57634 3.810639 0.141473 
TRRAP 8295 3.630418 0.191103 
NUP62 23636 3.429893 0.005683 
GPR147 64106 3.306154 0.020687 
CIC 23152 3.295524 0.62247 
SKIL 6498 3.288141 0.754046 
WBP11 51729 3.255237 0.057564 
SETD5 55209 3.215081 0.840927 
NFE2 4778 3.178993 0.791428 
ILF2 3608 3.030825 0.433237 
ZNF48 197407 2.945386 0.725935 
PLK1 5347 2.875995 0.00659 
PRPF6 24148 2.812959 0.53907 
EIF4A3 9775 2.799675 0.045809 
PSMC2 5701 2.738937 0.030004 
FANCD2 2177 2.669228 0.571213 
NFKB2 4791 2.649079 0.595565 
ZNF140 7699 2.645623 0.708664 
HSF1 3297 2.645199 0.492832 
ZBTB12 221527 2.612779 1.025685 
ZNF354C 30832 2.522182 0.601728 
HDAC3 8841 2.504701 0.869307 
ILF3 3609 2.474084 0.627961 
LSM7 51690 2.466111 0.429191 
SFPQ 6421 2.441514 0.023494 
TFDP2 7029 2.435719 0.625072 
GABPA 2551 2.409886 0.219587 
SNRPE 6635 2.364563 0.07831 
DMAP1 55929 2.362587 0.148349 
LEF1 51176 2.362138 1.053546 
TICRR 90381 2.327715 0.35001 
CDK11A 728642 2.313449 0.065421 
GMEB1 10691 2.289803 0.724297 
SNRPD1 6632 2.222764 0.044145 
CCDC6 8030 2.210449 0.843268 
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ZBTB46 140685 2.198587 0.651346 
DDX18 8886 2.194596 0.366266 
KIAA1310 55683 2.179639 0.392174 
AURKA 6790 2.177545 0.465421 
DHX58 79132 2.173781 0.966479 
CDC25A 993 2.169595 0.357658 
IKZF4 64375 2.15197 0.666883 
TRIM8 81603 2.145776 0.780171 
SNRNP200 23020 2.137963 0.193514 
DDX6 1656 2.130468 0.662929 
ACTL6A 86 2.124824 0.181861 
SF3B1 23451 2.121826 0.05737 
TGIF1 7050 2.116383 0.836561 
DMRTB1 63948 2.096732 0.481029 
UBE2L3 7332 2.067143 0.543246 
NDN 4692 2.044973 0.680173 
VPS72 6944 2.038468 0.84245 
RFC2 5982 2.001052 0.481757 
MCM5 4174 1.97192 0.784626 
DPF2 5977 1.968835 0.677575 
SAST 22983 1.932438 0.773356 
MDM4 4194 1.905858 0.485109 
DHX16 8449 1.859229 0.125329 
ERG 2078 1.852405 1.163113 
SRRM1 10250 1.850282 0.689112 
JMJD1A 55818 1.83454 1.051515 
ARID2 196528 1.811834 1.170976 
RYBP 23429 1.810047 0.6106 
GPS2 2874 1.791849 0.38294 
BAT1 7919 1.778783 0.215005 
KMT2C 58508 1.776583 0.94451 
EPHB2 2048 1.760731 0.488943 
ZNF782 158431 1.752058 1.01651 
ARID1A 8289 1.7448 0.604572 
ATF6B 1388 1.743112 0.79474 
CHAF1A 10036 1.738658 0.0624 
ETV5 2119 1.732212 0.523448 
TFAP2B 7021 1.725075 0.9827 
CREB3L2 64764 1.718285 0.381564 
ZNF22 7570 1.71809 0.746755 
JARID2 3720 1.706206 0.207434 
NUP153 9972 1.703549 0.100312 
CSNK2A1 1457 1.698509 0.907252 
MPND 84954 1.676003 0.887471 
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ACD 65057 1.670423 1.067412 
SAP30BP 29115 1.660069 0.439613 
HIST1H2BB 3018 1.640174 0.954668 
L3MBTL2 83746 1.635015 0.921015 
PLK3 1263 1.626303 0.755686 
SFRS3 6428 1.615708 0.216354 
SETMAR 6419 1.615242 0.548172 
H2AFZ 3015 1.612695 0.801535 
MAX 4149 1.610527 0.97528 
DUSP6 1848 1.60157 0.311926 
GMNN 51053 1.59494 0.661588 
GPR101 83550 1.591803 0.924384 
PKNOX2 63876 1.585563 0.82402 
CAMTA2 23125 1.585317 0.61444 
CXCR6 10663 1.56801 0.457659 
MEAF6 64769 1.563583 0.807328 
DDX19A 55308 1.548573 0.95648 
HKR1 284459 1.524105 1.105771 
ZFP36L1 677 1.520691 0.572518 
SCML4 256380 1.515937 0.952742 
MYST1 84148 1.506528 0.158914 
TAX1BP3 30851 1.500625 0.870139 
KLHL41 10324 1.495996 0.682487 
CHD3 1107 1.481632 0.385722 
ZNF619 285267 1.481501 0.530358 
NFXL1 152518 1.463693 0.874714 
PYGO1 26108 1.453645 0.130134 
HMGA1 3159 1.451076 0.499978 
TOX4 9878 1.445928 0.941139 
NTRK2 4915 1.440484 0.20639 
ZFAT 57623 1.435305 0.881581 
NPY 4852 1.434608 0.48115 
NEK2 4751 1.432953 1.086315 
BIRC5 332 1.422219 0.117054 
MARK2 2011 1.408215 0.656586 
SNIP1 79753 1.405112 0.094095 
JDP2 122953 1.400855 0.585662 
ADORA1 134 1.396769 0.520874 
ZNF574 64763 1.392161 0.235377 
MASS1 84059 1.38833 0.753752 
ASCC2 84164 1.367399 0.930258 
SNRNP27 11017 1.354516 0.73008 
PAX3 5077 1.339302 1.034505 
CSNK2B 1460 1.301955 0.716346 
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ESPL1 9700 1.299969 0.059506 
TLK1 9874 1.292012 1.143709 
MORF4 10934 1.281612 0.762226 
RBBP4 5928 1.277126 0.198751 
MPP3 4356 1.265657 0.190298 
SNRPB 6628 1.216005 0.085709 
RPS6KA1 6195 1.013957 0.293602 





Appendix 6. List of hits for the + Retinoic acid condition 
Gene Symbol Entrez Gene ID Mean Z-score Mean Cell Viability Score 
TAF1 6872 6.608557 0.672588 
SKIL 6498 5.961297 0.985128 
RBMX 27316 5.740771 0.681441 
WBP11 51729 4.932392 0.131931 
NFYC 4802 4.762958 0.766345 
SETD5 55209 4.694522 0.879323 
MLNR 2862 4.679523 1.039359 
RHO 6010 4.512082 1.018085 
ASF1A 25842 4.375268 0.848312 
ZNF707 286075 4.075265 0.985303 
FFAR1 2864 4.026534 1.084124 
CHAF1B 8208 3.962761 0.506476 
CDKL3 51265 3.904794 1.142033 
IRAK2 3656 3.818146 1.036585 
BRD4 23476 3.726535 0.778985 
CXADR 1525 3.680633 0.893693 
NEUROG2 63973 3.640891 1.194415 
CDK11A 728642 3.599464 0.144949 
ZBTB11 27107 3.537131 0.697197 
KLHL14 57565 3.53107 0.941069 
PPP2R1A 5518 3.521348 1.183597 
PTPRT 11122 3.513873 1.023442 
NFYB 4801 3.490615 0.725104 
ZNF140 7699 3.458326 0.840491 
DFFB 1677 3.456652 1.114096 
FRAP1 2475 3.433615 0.954868 
CCDC6 8030 3.383194 0.969125 
CEBPA 1050 3.35348 0.971558 
CIB2 10518 3.290305 0.679691 
PLRG1 5356 3.284123 0.371918 
TSG101 7251 3.279604 0.178139 
CHD8 57680 3.192836 0.974168 
GTF2IRD2B 389524 3.180282 0.947673 
MARK2 2011 3.155987 1.159295 
MC3R 4159 3.152512 0.341665 
WBP11 51729 3.146758 0.083127 
ETV5 2119 3.129495 0.881457 
ZBTB12 221527 3.043658 0.997157 
PKN2 5586 3.036973 1.10247 
GABPB1 2553 2.993346 0.332446 
ZNF317 57693 2.982855 0.861902 
ZNF192 7745 2.976632 0.934138 
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EP400 57634 2.961968 0.421063 
EFNA3 1944 2.953257 1.245154 
ASF1B 55723 2.943198 0.725666 
EPHB2 2048 2.92501 0.843684 
MYF5 4617 2.909644 0.989357 
SETD2 29072 2.899547 1.156641 
AKT1 207 2.888259 1.010932 
ATF7 11016 2.885865 0.89355 
PPFIA2 8499 2.813446 0.997352 
KIAA2002 79834 2.811388 1.101227 
NPAT 4863 2.789561 0.55651 
CCR6 1235 2.772246 0.94092 
RNPS1 10921 2.767186 0.384442 
PDK1 5163 2.760405 1.083311 
NKAP 79576 2.759491 0.126416 
NMUR1 10316 2.758763 0.910521 
TBX15 6913 2.758427 0.921128 
ANKZF1 55139 2.75236 0.982258 
MERTK 10461 2.746322 0.999175 
PVR 5817 2.734018 0.536562 
FRK 2444 2.733287 1.11919 
ZNF441 126068 2.715834 1.076417 
DHX38 9785 2.706779 0.292804 
ACD 65057 2.696886 0.938817 
BCL11A 53335 2.660337 1.044709 
CHD3 1107 2.656699 0.343878 
HIST1H1A 3024 2.651479 0.969417 
TFAP2B 7021 2.649261 0.969886 
DDX1 1653 2.637643 1.158055 
SNIP1 79753 2.618139 0.23333 
TCEB2 6923 2.610865 0.496504 
ASCC3 10973 2.608188 1.081167 
NEK1 4750 2.601714 1.145532 
GPR101 83550 2.586515 1.032186 
TAF2 6873 2.586196 1.163686 
ZNF226 7769 2.578861 0.848572 
ZNF354C 30832 2.573079 1.062939 
POLR2I 5438 2.567482 0.212402 
MAP2K3 5606 2.566121 1.193005 
PADI4 23569 2.559142 1.033419 
GPR18 2841 2.557716 0.982015 
ING5 84289 2.556089 1.043189 
MZF1 7593 2.555891 0.813358 
NUDT21 11051 2.554061 0.586026 
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PTPN12 5782 2.534503 1.074874 
SCAP1 8631 2.529485 1.252792 
PLK4 10733 2.504691 0.834073 
PON1 5444 2.502199 0.972084 
CHAF1A 10036 2.488923 0.539164 
GZF1 64412 2.460614 1.039601 
MED26 9441 2.455073 0.321475 
TRRAP 8295 2.452951 0.372737 
SFMBT1 51460 2.428209 1.06154 
ZFP57 346171 2.426377 0.998124 
ZNF79 7633 2.424132 0.606429 
ZSCAN32 54925 2.423906 1.095694 
DHX9 1660 2.418265 1.024849 
ZNF619 285267 2.412454 0.976275 
HMGA1 3159 2.412244 0.949968 
ILF3 3609 2.40397 1.044045 
ADORA2A 135 2.396333 0.958711 
SIN3A 25942 2.389798 0.519032 
SP2 6668 2.345387 0.972043 
USE1 55850 2.335257 0.548172 
PPP1R13B 23368 2.320487 1.059457 
TCF23 150921 2.315445 1.131012 
ZNF532 55205 2.314937 1.102752 
ATXN2 6311 2.31355 1.121691 
PMVK 10654 2.312961 1.165157 
TRIB3 57761 2.307221 0.431334 
URKL1 54963 2.305345 1.146269 
CIAO1 9391 2.285529 0.834677 
PSMC2 5701 2.285375 0.059163 
HDAC6 10013 2.269314 0.947187 
KHK 3795 2.263077 1.212515 
DDX28 55794 2.262938 0.999503 
ZNF207 7756 2.234563 0.349732 
MRGPRX4 117196 2.232668 1.044715 
DUSP4 1846 2.224797 1.062662 
GABPA 2551 2.214518 0.327658 
ZNF2 7549 2.214452 0.957617 
ZNF154 7710 2.209309 0.877216 
GTF2H1 2965 2.207691 0.927566 
TUBA1B 10376 2.201631 0.358028 
SNRPN 6638 2.199508 0.965584 
PHB2 11331 2.184548 0.379605 
CIC 23152 2.181712 0.838143 
SFRS6 6431 2.166749 0.772448 
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ZNF668 79759 2.165083 1.152706 
SMARCD2 6603 2.163007 0.995018 
DHX58 79132 2.162601 1.131214 
GUK1 2987 2.157346 0.480052 
SOX7 83595 2.156989 1.02067 
AK5 26289 2.156125 0.933279 
PHF7 51533 2.154314 1.012255 
CAMTA2 23125 2.152327 0.954164 
POLR2C 5432 2.14222 0.1184 
ZNF467 168544 2.128767 0.847746 
DHX33 56919 2.127794 0.827236 
AGTR1 185 2.125032 1.076853 
GPR44 11251 2.121728 0.857756 
CCRK 23552 2.09963 1.225904 
CNOT2 4848 2.094046 0.748952 
RXRA 6256 2.091618 1.049529 
KDM4D 55693 2.090811 1.052768 
MED31 51003 2.087189 0.732073 
TFDP2 7029 2.086706 0.754933 
DHX8 1659 2.085239 0.113291 
MMP9 4318 2.083827 0.318174 
CKMT2 1160 2.08025 1.200875 
ZNF212 7988 2.079028 1.033086 
ATF6B 1388 2.077408 0.909917 
VEGFA 7422 2.076966 1.047638 
GAK 2580 2.072499 0.562777 
PRKCL2 5586 2.070978 0.970255 
HMGA2 8091 2.06746 0.848229 
BRD4 23476 2.06372 0.934712 
EEF1A1 1915 2.063124 0.220679 
ARID1A 8289 2.062662 0.907839 
CALCOCO1 57658 2.062361 1.044775 
EIF5B 9669 2.058996 0.72722 
NFATC3 4775 2.058429 1.077119 
HMGXB3 22993 2.057697 0.296634 
KUB3 91419 2.057408 1.226778 
PRPF6 24148 2.055437 0.507785 
ANKRD6 22881 2.055124 0.953723 
CDK5 1020 2.049546 1.010251 
SMC2 10592 2.048696 0.69066 
TTBK1 84630 2.043131 1.179032 
ZNF782 158431 2.040877 1.025315 
RFXAP 5994 2.036599 1.068578 
JAK1 3716 2.029144 1.082776 
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ZFP42 132625 2.019272 1.049466 
RUVBL2 10856 2.016043 0.160336 
ZBTB6 10773 2.010123 0.893377 
RAP1GAP 5909 2.00957 0.802694 
CDKN2C 1031 2.008508 1.284162 
DNMT1 1786 2.004839 1.043459 
SNRNP200 23020 2.000804 0.137003 
POLR3E 55718 1.994337 0.637038 
HMGN1 3150 1.991516 0.799106 
GTF2H1 2965 1.988693 0.95328 
TAL2 6887 1.977656 1.029222 
NKX3-2 579 1.96051 1.031935 
H1F0 3005 1.959344 0.986053 
KCNH8 131096 1.951063 1.046875 
GTF2H4 2968 1.948488 0.984776 
PAK7 57144 1.937819 0.964427 
ZFAND3 60685 1.937552 0.840348 
EVX2 344191 1.935099 0.912368 
BUD31 8896 1.932619 0.098543 
MAP3K10 4294 1.92729 1.116724 
CDK9 1025 1.92487 0.625604 
FHL1 2273 1.923802 0.766709 
POLR2H 5437 1.918986 0.180686 
DIP2B 57609 1.918699 1.029573 
HDAC11 79885 1.910072 1.120867 
CBFA2T3 863 1.899169 0.387933 
POLR2L 5441 1.897246 0.340649 
POLR2D 5433 1.896288 0.070567 
CDC42BPA 8476 1.875172 1.15843 
ESPL1 9700 1.873263 0.375823 
PHF19 26147 1.87238 0.23382 
SETD8 387893 1.868008 0.183135 
PYGO1 26108 1.867475 0.472932 
TAF1 6872 1.86728 0.857286 
NFATC2 4773 1.865802 0.654839 
GPR157 80045 1.863016 1.03157 
KIAA1310 55683 1.858318 0.305745 
RNF113A 7737 1.850884 1.114593 
ZFP36 7538 1.850168 0.828363 
ZNF215 7762 1.84555 1.069404 
SUGP1 57794 1.844163 1.11175 
YY1 7528 1.841999 1.000052 
SMARCA5 8467 1.839925 1.137309 
MAF1 84232 1.833559 1.225161 
 147 
 
SNRPD1 6632 1.830657 0.254661 
SAP18 10284 1.830294 0.885024 
AEBP2 121536 1.818966 1.069476 
TA-PP2C 160760 1.81555 1.165046 
PIK3CD 5293 1.813079 1.219739 
UBTF 7343 1.812966 0.841507 
PTGS2 5743 1.811386 1.049819 
TESK1 7016 1.809663 1.022506 
PIK3C2A 5286 1.809448 1.083858 
GPRC5C 55890 1.796335 1.13993 
EVI1 2122 1.795074 1.093359 
CASR 846 1.790111 0.999492 
PIAS1 8554 1.787799 0.947417 
ZNF396 252884 1.785548 0.232572 
SKIV2L 6499 1.782419 1.138005 
HIST1H2AH 85235 1.771539 0.959616 
SYK 6850 1.769253 1.062341 
ZNF75D 7626 1.768371 0.937129 
ZNF259 8882 1.767814 0.990059 
ZFP112 7771 1.761642 1.087045 
SSX2 6757 1.760966 0.961949 
ZNF709 163051 1.758862 0.922181 
DGUOK 1716 1.752543 1.004862 
ZBTB46 140685 1.751421 0.94292 
UBE2K 3093 1.748684 1.102903 
AGAP3 116988 1.747745 1.077434 
PPAP2B 8613 1.747704 1.045103 
MPP3 4356 1.747008 0.822777 
HELZ2 85441 1.746732 1.094994 
PKMYT1 9088 1.746249 1.048993 
VHL 7428 1.731148 0.984836 
SNURF 0 1.730748 1.044642 
TUBA1C 84790 1.720925 1.096472 
MMS19 64210 1.717978 1.128329 
GPR65 8477 1.716955 1.019322 
HELT 391723 1.714972 0.892647 
DLG2 1740 1.71305 1.061361 
MARK4 57787 1.710763 0.894343 
PRKCB 5579 1.710599 1.092583 
NFXL1 152518 1.70753 0.985756 
RFC2 5982 1.707029 0.78658 
MPND 84954 1.705249 1.076496 
KDM5B 10765 1.695557 0.985859 
POLR1E 64425 1.68921 1.019065 
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HRH2 3274 1.677022 0.998784 
STAT1 6772 1.670454 1.025621 
MAPKAPK3 7867 1.668271 1.278873 
CCDC67 159989 1.663355 1.103498 
POLR2F 5435 1.660021 0.102977 
NFYA 4800 1.658947 0.402536 
L3MBTL 26013 1.654855 0.980413 
POU4F3 5459 1.650159 0.729711 
ZNF772 400720 1.642743 0.82177 
CTNNBL1 56259 1.637794 0.883979 
TRIM29 23650 1.634918 1.216643 
PROP1 5626 1.632856 0.46534 
KAT2B 8850 1.625278 1.10763 
ZBED2 79413 1.624771 1.005634 
GPR141 353345 1.620593 1.15372 
ZNF200 7752 1.616548 0.925347 
ZNF227 7770 1.61198 1.111626 
ZNF485 220992 1.603201 1.144446 
GCC2 9648 1.599156 1.024341 
SMAD3 4088 1.596292 0.813216 
MAFA 389692 1.587636 1.099492 
ZNF239 8187 1.586478 1.081891 
ZNF416 55659 1.579751 0.882693 
MEF2B 0 1.574541 0.890167 
EYA4 2070 1.574434 1.081472 
NUDT2 318 1.572086 1.089536 
TRAF6 7189 1.565043 1.017594 
DDX41 51428 1.549409 0.19565 
SOX9 6662 1.544943 0.970958 
SUPT20H 55578 1.541065 1.142956 
POU4F1 5457 1.539879 1.094733 
TRAF5 7188 1.53854 1.005842 
SCAND2 54581 1.522487 1.04344 
MXD3 83463 1.522485 1.012511 
ZNF266 10781 1.509767 1.052183 
ZSCAN2 54993 1.509006 1.10666 
ZNF860 344787 1.504266 1.144657 
ZNF273 10793 1.489337 0.963982 
DUSP12 11266 1.488376 0.944269 
MTA1 9112 1.488106 1.019468 
TIMM50 92609 1.484426 1.058261 
HINFP 25988 1.459763 0.859232 
DUSP6 1848 1.456161 0.883148 
ZNF776 284309 1.438796 1.034583 
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PNN 5411 1.435147 0.776129 
FOXR1 283150 1.425075 1.143995 
TBL1XR1 79718 1.421482 1.082033 
POU1F1 5449 1.421405 1.049736 
PPP3R2 5535 1.380098 1.104494 
SMAD4 4089 1.368683 1.223986 
SPEN 23013 1.348423 0.884493 
E2F5 1875 1.339401 1.011681 
SLC2A4RG 56731 1.320798 0.894955 
TRMT11 60487 1.316348 0.967644 
C9ORF67 84814 1.316073 0.97041 
ZIC3 7547 1.298578 0.895853 
NUP153 9972 1.294525 0.574038 
TAF8 129685 1.279132 0.967674 
PPP2CZ 333926 1.277532 1.164914 
TAF9 6880 1.267752 0.93178 
ARNT 405 1.203382 1.000856 
PPAPDC1 196051 1.174661 1.091659 
PPM1F 9647 1.162985 1.150928 
CASP2 835 1.121582 1.061862 
XBP1 7494 1.109072 0.896269 
EYA3 2140 1.063191 0.943605 
STK10 6793 1.022171 1.045349 
 
